| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Mesoblast Limited$15.44
+0.63 (+4.25%)
B 66Pipeline Score Undervalued Biotech · Commercial
Market Cap
1.95 B
EPS
-0.74
P/E Ratio
-
Value Trade
1.57 M
0.8 %
Week
-4.88 %
1 Month
-10.01 %
3 Month
3.26 %
6 Month
2.01 %
5 Year
220 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
292.52 K
52 Week Range
9.88 - 21.50
% held by Insiders
-
% held by Institutions
2.58 %
Enterprise Value
1.96 B
Total Shares
129.28 M
Short %
2.42 %
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mesoblast Limited
1082Total events
11Upcoming
374Tier-1 (high impact)
2014 – 2044Coverage
Upcoming catalysts 11
Dec 2036
T2Exclusivity Granted
Biologic exclusivity preventing biosimilar referencing until December 2036
2044
T2Patent Granted
U.S. intellectual property on MSC composition of matter, manufacturing and indications providing commercial barrier through 2044
2044
T2Patent Granted
IP protection through 2044 for MSC composition of matter, manufacturing, and indications
TBD
T3Enrollment Milestone
Onboarded 32 transplant centers; aim to onboard top 45 centers by end of quarter
Event history 1071
Jun 30, 2026
▲FDA Filing AcceptedRexlemestrocel-L + HA mixtureApprovedRegulatory Filing
Received BLA filing number from FDA
prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD)source ↗
Q2 2026
◆Trial InitiationRyoncilApprovedTrial
First sites to be activated for Ryoncil adult SR-aGvHD label extension trial
steroid-refractory acute graft versus host disease (SR-aGvHD) in adultssource ↗
Jun 30, 2026
Jun 24, 2026
▲Debt Royalty FinancingCorporate
Drew down US$50 million from five-year non-dilutive facility
Jun 2026
▲First Patient DosedRemestemcel-L-rkndApprovedTrial
Adult SR-aGvHD trial initiated with BMT-CTN network
Adult SR-aGvHDsource ↗
Jun 2026
▲IND ClearanceRemestemcel-L-rkndApprovedIND
FDA cleared IND for pediatric Duchenne's Phase 3
Duchenne Muscular Dystrophysource ↗
Jun 2026
▲Debt Royalty FinancingCorporate
Partly repaid subordinated royalty facility; expected to be fully repaid by mid-CY2026
Jun 2026
▲Quarterly UpdateRyoncilApprovedCorporate
FY2026 net revenue guidance for Ryoncil: US$110-120 million
steroid-refractory acute graft versus host disease (SR-aGvHD)source ↗
Apr 28, 2026
▲Enrollment CompleteRexlemestrocel-L + HA mixtureApprovedTrial
Patient recruitment target achieved in pivotal Phase 3 trial
chronic low back pain associated with degenerative disc diseasesource ↗
Apr 15, 2026
▲Partnership / LicenseCorporate
Mesoblast acquires exclusive worldwide license to patented CAR technology platform for MSC products
Apr 14, 2026
▲Partnership / LicenseCorporate
Acquired exclusive worldwide license to patented CAR technology platform from Mayo Clinic
Drug Pipeline Intelligence
B66
Pipeline Score $13.5B
Pipeline ValueUndervalued
Valuation Signal17
Drugs Scored6.9x
rNPV / MCap Top 92%
Micro Cap (rank 74 of 911)
Percentile RankMesoblast Limited holds a solid B-grade pipeline (66/100), with $36.4B risk-adjusted pipeline value, led by Rexlemestrocel-L + HA mixture in Degenerative Disc Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rexlemestrocel-L + HA mixture Small molecule | Degenerative Disc Disease | Phase 3 | NCT06325566 | 90% | $16.9B | ACTIVE NOT_RECRUITING | 704 | VERY_FAST | B (62) | Jul 1, 2028 | LOW_RISK | MEDIUM Jun 18, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ryoncil BreakthroughPriorityOrphan | steroid-refractory acute graft-versus-host disease (SR-aGvHD) | Phase 3 | 2026-02-12 | 15% died before being able to complete a full treatment course of Ryoncil compared with only 2% of patients who received Ryoncil as second-line in the Phase 3 trial MSB-GVHD001; adult patients in the EIND program of Ryoncil had at least as favorable day 100 survival as children in the EIND program Read More | ryoncileindatt HIGH SURVIVAL RATES WITH RYONCIL IN EIND PROGRAM EMPHASIZE IMPORTANCE OF EARLIER USE IN BOTH CHILDREN AND ADULTS WITH SR-aGvHD New York, USA: February 11 and Melbourne, Australia Read More | |
Ryoncil BreakthroughPriorityOrphan | steroid-refractory acute graft-versus-host disease (SR-aGvHD) | Phase 3 | 2026-02-12 | 15% died before being able to complete a full treatment course of Ryoncil compared with only 2% of patients who received Ryoncil as second-line in the Phase 3 trial MSB-GVHD001; adult patients in the EIND program of Ryoncil had at least as favorable day 100 survival as children in the EIND program Read More | ryoncileindatt HIGH SURVIVAL RATES WITH RYONCIL IN EIND PROGRAM EMPHASIZE IMPORTANCE OF EARLIER USE IN BOTH CHILDREN AND ADULTS WITH SR-aGvHD New York, USA: February 11 and Melbourne, Australia Read More | |
Ryoncil BreakthroughPriorityOrphan | steroid-refractory acute graft-versus-host disease (SR-aGvHD) | Phase 3 | 2026-02-12 | 15% died before being able to complete a full treatment course of Ryoncil compared with only 2% of patients who received Ryoncil as second-line in the Phase 3 trial MSB-GVHD001; adult patients in the EIND program of Ryoncil had at least as favorable day 100 survival as children in the EIND program Read More | ryoncileindatt HIGH SURVIVAL RATES WITH RYONCIL IN EIND PROGRAM EMPHASIZE IMPORTANCE OF EARLIER USE IN BOTH CHILDREN AND ADULTS WITH SR-aGvHD New York, USA: February 11 and Melbourne, Australia Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MESO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MESO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MESOMesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
Mesoblast Limited has received a Biologics License Application (BLA) filing number from the FDA and has requested a modular review for its product rexlemestrocel-L. This therapy aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients with LVADs. The product has received Orphan Drug and RMAT designations, allowing for priority review. The FDA's recent guidance indicates a flexible approach to products for rare diseases.
Read more →MESO▼ -6.8%on this news
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Mesoblast Limited has drawn US$50 million from a five-year non-dilutive facility provided by Dr. Gregory George. This funding will help the company retire short-term high-cost debt and strengthen its balance sheet. With US$122 million cash on hand, Mesoblast is positioned to invest in its commercial operations and growth pipeline.
Read more →MESOThis presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our
Mesoblast recently presented a compelling overview of its forward-looking strategies and expectations regarding future financial performance. The presentation highlighted their foundational successes, including the successful commercialization of Ryoncil, their first FDA-approved product, which has generated significant revenue. Mesoblast is focused on expanding its pipeline with advanced cellular therapies for various severe conditions, leveraging their proprietary technology in stem cell medicine. However, the company acknowledges inherent risks and uncertainties in clinical trials, regulatory approvals, and market dynamics.
Read more →MESOMesoblast Reports Ryoncil Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Mesoblast Limited reported strong financial performance with net revenues of US$30.3 million for the quarter and total Ryoncil sales nearing US$100 million since its launch. The company achieved its patient recruitment target for a pivotal phase 3 trial on chronic low back pain, signaling progress in clinical development. Additionally, Mesoblast has improved its net operating cash spend and secured an exclusive license for a new CAR technology to enhance therapeutic offerings. These advancements mark significant milestones for the company in the biopharma sector.
Read more →MESOOther Fees to Non-Executive Directors were US$156,048, consulting payments to Non-Executive Directors were US$150,000, and salary payments to full-time Executive Directors were US$399,070, detailed in Item 6 of the Appen
Mesoblast Limited has reported significant financial progress for the third fiscal quarter ended March 31, 2026, with Ryoncil revenues nearing US$100 million since its launch. The company also achieved its patient recruitment target for a pivotal Phase 3 trial aimed at treating chronic low back pain. Furthermore, Mesoblast has made advancements in its cellular therapy technologies, acquiring a patented CAR technology platform to enhance its product efficacy. The reduction in net operating cash expenditure indicates improved financial management.
Read more →MESOMesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Limited has successfully met its patient recruitment target for a pivotal Phase 3 trial of rexlemestrocel-L, aimed at treating chronic low back pain due to degenerative disc disease. The trial will involve over 300 patients and seeks to confirm earlier positive results regarding pain reduction and opioid usage. Top-line results are anticipated in mid-2027, with a regulatory filing expected in Q3 2027.
Read more →MESOAbout Chronic Low Back Pain Back pain is the leading cause of disability in Americans under 45 years,1 with an annual prevalence in the general US adult population of 10-30%.2 CLBP caused by inflammation and degenerative
Mesoblast Limited has successfully reached its patient recruitment target for the pivotal Phase 3 trial of rexlemestrocel-L in treating chronic low back pain (CLBP) related to degenerative disc disease. This achievement is a critical step toward commercializing the therapy, which aims to offer a non-opioid alternative for patients suffering from CLBP—a condition affecting over 7 million individuals in the U.S. With positive results expected to support regulatory filing in 2027, Mesoblast is on track to address a significant unmet medical need in this patient population.
Read more →MESOAppendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2 3437-3947-1947, v. 1 Class See above Number acquired 70,000 ADS, each representing 10 ordinary shares; an
Gregory George, a director of Mesoblast Limited, has reported a change in his interest regarding securities of the company. He acquired a total of 70,000 American Depositary Shares (ADSs) and over 7 million ordinary shares, with a total consideration of approximately $11.4 million. This acquisition suggests a strong belief in the company's potential and may have an impact on market perception. No securities were disposed of during this reporting period.
Read more →MESO▲ +7.8%on this newsshared move
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
Mesoblast Limited has acquired an exclusive worldwide license for a patented chimeric antigen receptor (CAR) technology platform. This acquisition aims to enhance the effectiveness of Mesoblast's mesenchymal lineage stromal cell (MSC) products, particularly for inflammatory diseases. The technology, developed by Mayo Clinic, is expected to improve targeting and potency of treatments for conditions like ulcerative colitis and Lupus Nephritis.
Read more →MESO▲ +7.8%on this newsshared move
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of
Mesoblast Limited has acquired an exclusive worldwide license for a patented chimeric antigen receptor (CAR) technology platform aimed at enhancing the potency of its mesenchymal lineage stromal cell (MSC) products. This technology is set to improve targeted homing to inflamed tissues, with applications for inflammatory diseases such as ulcerative colitis and Lupus Nephritis. Mesoblast's strong intellectual property portfolio, comprising over 1,000 patents, will provide commercial protection for its innovative therapies well into the future. The Mayo Clinic, which developed the foundational CAR technology, will support Mesoblast in advancing this promising platform.
Read more →MESOMesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy - CORRECTION
Mesoblast Limited has received Investigational New Drug (IND) clearance from the FDA to start a registrational clinical trial for Ryoncil in treating Duchenne muscular dystrophy (DMD). This trial involves randomizing 76 patients aged 5 to 9 years who will receive either Ryoncil or a placebo in addition to standard care, with the primary endpoint being time-to-stand at nine months. The initiative aims to leverage Ryoncil's anti-inflammatory properties to preserve muscle function and slow disease progression in affected children.
Read more →MESOMesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Mesoblast Limited has received FDA clearance to proceed with a registrational trial for Ryoncil® in treating Duchenne muscular dystrophy (DMD). This trial will evaluate the efficacy of Ryoncil® in children aged 5 to 9 years, aiming to leverage its anti-inflammatory properties to slow disease progression. The company is partnering with Parent Project Muscular Dystrophy to facilitate patient engagement and trial awareness.
Read more →MESOinflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual pr
Mesoblast Limited is showcasing significant commercial progress and platform innovation during its inaugural R&D Day. The company is on the verge of achieving nearly US$100 million in net revenues from its product Ryoncil, which targets severe inflammatory conditions. They are also advancing clinical trials for chronic low back pain and heart failure treatments, alongside expanding their partnerships globally. Additionally, Mesoblast has acquired innovative CAR technology to enhance their therapeutic offerings, underlining their commitment to innovation in regenerative medicine.
Read more →MESOAbout Parent Project Muscular Dystrophy Parent Project Muscular Dystrophy (PPMD), a leading patient advocacy organization, to support patient identification, education, and trial awareness. The organization was founded i
Mesoblast Limited has received Investigational New Drug (IND) clearance from the FDA to proceed with a registrational trial for Ryoncil aimed at treating Duchenne muscular dystrophy (DMD). The trial, involving 76 patients aged 5 to 9, will assess the efficacy of Ryoncil in enhancing muscle function and slowing disease progression. Mesoblast is partnering with Parent Project Muscular Dystrophy to improve patient identification and trial awareness. The anticipated outcomes are promising, potentially offering new hope for children affected by this debilitating condition.
Read more →MESOMesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Mesoblast Limited is showcasing significant commercial progress during its inaugural R&D Day, aiming to double net revenues as Ryoncil approaches a $100 million revenue milestone. Key developments include the close of enrollment for a Phase 3 trial in chronic low back pain and FDA clearance for a registrational trial of Ryoncil in children with Duchenne muscular dystrophy. The company is also introducing new therapeutic products for inflammatory conditions and has acquired innovative CAR technology. Mesoblast continues to lead in allogeneic cellular medicines, with plans for further revenue growth and expanded clinical applications.
Read more →MESO▼ -8%on this newsshared move
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
Mesoblast Limited reported strong sales of Ryoncil® with net revenues of US$30.3 million for the quarter ending March 31, 2026. The total revenue since the product's launch is nearing US$100 million, indicating solid market performance. The company plans to discuss its growth strategy and product pipeline at an upcoming R&D event.
Read more →MESO▲ +7%on this news
About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteri
Mesoblast Limited announced strong sales of its product Ryoncil, reaching $30.3 million for the March quarter and nearing $100 million in total revenue since its launch. Ryoncil, an FDA-approved treatment for steroid-refractory acute graft-versus-host disease in pediatric patients, is expected to support additional label expansions and late-stage programs. The company plans to detail its growth strategy at its inaugural R&D event on April 8, 2026, in New York City. Mesoblast continues to lead in developing off-the-shelf cellular medicines for severe inflammatory conditions.
Read more →MESOAppendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change 78,958,928 ordinary shares, held as follows: Direct: 67,756,838 ordin
The article announces a change in director's interests at Mesoblast Limited. Specifically, Dr. Silviu Itescu and Dr. Eric Rose updated their securities holdings, including options and ordinary shares. Dr. Itescu now holds a total of 78,958,928 shares, while Dr. Rose increased his options to 6,413,451. This report fulfills ASX listing rule requirements regarding director interests.
Read more →MESOMesoblast to Host R&D Day on April 8, 2026
Mesoblast Limited will host its inaugural R&D Day on April 8, 2026, in New York City. The event will feature presentations from senior leadership and key opinion leaders, focusing on corporate strategy and the commercialization of Ryoncil®. Additionally, the company will introduce new technology aimed at enhancing cellular medicine innovation.
Read more →MESOForward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that
Mesoblast Limited is set to host its inaugural R&D Day on April 8, 2026, in New York City, highlighting the company's corporate strategy and its multi-billion-dollar pipeline in treating inflammatory diseases and cardiovascular conditions. The event will include presentations from the senior leadership team and key opinion leaders, and will discuss the successful commercialization of its flagship product, Ryoncil. Innovations in cellular medicines technology are also anticipated during the event. However, the press release contains forward-looking statements that emphasize uncertainties and risks that could impact future performance.
Read more →MESOappendix3ydrge Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's prope
Mesoblast Limited disclosed significant changes in director Gregory George's interest, reflecting an increase in holdings of shares and American Depositary Shares (ADS). After the changes, George's direct and indirect holdings now amount to over 19 million ADS. The total value of the shares acquired during this period was approximately $16.37 million. Such transactions must be reported to the ASX under the listing rule 3.19A.2 to maintain transparency regarding director interests.
Read more →MESOmaappointment DR. TERESA MONTAGUT APPOINTED AS CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS HEAD AT MESOBLAST New York, USA: March 11 and Melbourne, Australia
Mesoblast Limited has appointed Dr. Teresa Montagut as the new Head of Clinical Development and Medical Affairs. Reporting to Dr. Eric Rose, she will spearhead initiatives to foster clinical collaborations and enhance medical communications. Her extensive background in leading medical affairs and clinical trials will play a crucial role in advancing Mesoblast's cell therapy programs. This strategic appointment aims to unlock the potential of their FDA-approved product Ryoncil in various inflammatory conditions.
Read more →MESO▼ -6.3%on this news
Ryoncil® Profits Underpinning Substantial Growth Pipeline
Mesoblast Limited reported strong financial results for the first half of FY2026, primarily driven by the successful commercial launch of Ryoncil®. The company anticipates net revenue from Ryoncil® to reach between $110 million and $120 million for the fiscal year. CEO Dr. Silviu Itescu highlighted the company's improved financial position and focus on expanding commercial uptake and regulatory opportunities.
Read more →MESO▼ -6.3%on this newsshared move
h12026results RYONCIL PROFITS UNDERPINNING SUBSTANTIAL GROWTH PIPELINE Financial Results and Operational Update for Half-Year Ended
Mesoblast Limited reported strong financial results for the first half of FY2026, highlighting significant revenue growth driven by the successful launch of Ryoncil. The company anticipates full-year net revenue to reach between $110 million and $120 million, supported by improved operational performance. Despite a net loss of $40.2 million, this marks an improvement over the prior year. The company is poised to expand Ryoncil's indications and is progressing with its second-generation product, rexlemestrocel-L.
Read more →MESO▼ -6.3%on this newsshared move
Mesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2025 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
Mesoblast Limited has reported significant financial results for the half-year ending December 31, 2025. The company experienced a remarkable increase in revenues, rising by 1527% to $51,342,000. However, it continues to report a net loss of $40,162,000, although this figure represents a 16% decrease from the previous period. There were no dividends declared for this reporting period, and a substantial portion of the company's assets remains intangible.
Read more →MESOMesoblast Financial Results and Corporate Update Webcast
Mesoblast Limited will host a webcast on February 26, 2026, to discuss its operational highlights and financial results for the half year ending December 31, 2025. The company focuses on developing allogeneic cellular medicines for severe inflammatory diseases and has a strong intellectual property portfolio. Ryoncil, its FDA-approved therapy, is being expanded for additional indications.
Read more →MESOwebcastnoticef MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST New York, USA: February 20 and Melbourne, Australia
Mesoblast Limited is set to host a webcast on February 26, 2026, to discuss operational highlights and financial results for the half year ending December 31, 2025. The company is recognized as a leader in developing allogeneic cellular medicines, particularly for severe inflammatory diseases. Its lead therapy, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy. Mesoblast has a strong global intellectual property portfolio and is actively developing additional cell therapies for various indications.
Read more →MESO▼ -7.7%on this news
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Mesoblast Limited presented data indicating that Ryoncil® (remestemcel-L-rknd) shows high survival rates in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The results highlight the importance of early treatment initiation, with a pivotal trial planned for adults. Ryoncil® is the first FDA-approved MSC therapy for this condition.
Read more →MESO▼ -7.7%on this newsshared move
ryoncileindatt HIGH SURVIVAL RATES WITH RYONCIL IN EIND PROGRAM EMPHASIZE IMPORTANCE OF EARLIER USE IN BOTH CHILDREN AND ADULTS WITH SR-aGvHD New York, USA: February 11 and Melbourne, Australia
Mesoblast Limited announced encouraging results regarding the use of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) during the February 2026 Tandem Meetings. The data showed that Ryoncil achieved high survival rates in both children and adults, highlighting the necessity for its early application. The company plans to initiate a pivotal trial for adult patients following protocol approval, aiming to establish Ryoncil as a second-line treatment for SR-aGvHD. This treatment is particularly significant as the adult population for this condition is substantially larger than that of pediatric patients.
Read more →MESORyoncil® Net Revenues Increase for the Quarter to US$30M
Mesoblast Limited reported a strong financial performance for the quarter ending December 31, 2025, with Ryoncil® net revenues reaching US$30 million. The company also secured a new non-dilutive financing facility, enhancing its ability to pursue strategic partnerships and expand the label for Ryoncil®. These developments highlight Mesoblast's commitment to advancing its allogeneic cellular medicines for inflammatory diseases.
Read more →MESOappendix4cq2fy RYONCIL NET REVENUES INCREASE FOR THE QUARTER TO US$30M Activity Report for Quarter Ended
Mesoblast Limited reported strong financial results for the second fiscal quarter of 2025, with Ryoncil net revenues reaching $30 million, a noteworthy increase of 60% from the prior quarter. The company established a new non-dilutive credit facility, enhancing its strategic partnership opportunities and enabling efforts towards the expansion of Ryoncil's label. Operationally, promising results emerged from Ryoncil's use in pediatric patients facing acute graft-versus-host disease. Furthermore, the FDA expressed positive feedback regarding Mesoblast's potential filing for rexlemestrocel-L, supporting the company's continued innovation in cell therapies.
Read more →MESOReal-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Mesoblast Limited reported that 84% of children treated with Ryoncil® for steroid-refractory acute graft-versus-host disease (SR-aGvHD) survived after completing the initial 28-day treatment regimen. The company aims to expand Ryoncil®'s FDA label to include adults with severe SR-aGvHD, which represents a larger market. The treatment has been made accessible through a patient access hub, and significant payer coverage is already in place.
Read more →MESOrealworldexper REAL-WORLD COMMERCIAL EXPERIENCE WITH RYONCIL SHOWS 84% SURVIVAL OF CHILDREN WITH SR-aGvHD AFTER COMPLETING 28-DAYS OF TREATMENT New York, USA: January 26 and Melbourne, Australia
Mesoblast Limited reported early results indicating that its product Ryoncil (remestemcel-L-rknd) achieved an 84% survival rate among children with steroid-refractory acute graft-vs-host disease (SR-aGvHD) after 28 days of treatment. This data was gathered from the first 25 patients treated since Ryoncil became commercially available in March 2025. Mesoblast is expanding its efforts to onboard more transplant centers while simultaneously working to broaden Ryoncil's FDA approval to include adult patients with severe SR-aGvHD. The company emphasizes the importance of early treatment initiation for improving survival outcomes.
Read more →MESOFDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
Mesoblast Limited received positive feedback from the FDA regarding its allogeneic cell therapy, rexlemestrocel-L, for chronic low back pain. The FDA confirmed that the therapy demonstrated a clinically meaningful reduction in pain intensity over 12 months, supporting its efficacy. The company is actively recruiting for a second Phase 3 trial, which aims to further validate these findings and explore opioid reduction benefits.
Read more →MESOfdaconfirmspat FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY Approval Label May Include Opioid Reduction New York, USA: January 18 a
Mesoblast Limited received positive feedback from the FDA regarding its allogeneic cell therapy product rexlemestrocel-L, which aims to treat chronic discogenic low back pain (CLBP). The FDA confirmed that data from a Phase 3 trial indicated a significant reduction in pain intensity over 12 months. Additionally, this therapy may contribute to opioid reduction, addressing a critical issue in the U.S. opioid crisis. Mesoblast is now preparing for a potential Biologics License Application filing based on these findings.
Read more →MESOappendix3h3g Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of
Mesoblast Limited has announced a cessation of certain securities, specifically MSBAI options, which includes the lapse of 1,300,333 conditional securities and the expiration of 150,000 options. These developments are due to unfulfilled conditions and options expiring without being exercised. As a result, the company's issued capital will reflect a decrease corresponding to these ceasing securities. The announcement was made on January 15, 2026, detailing the changes in the company's securities on the ASX.
Read more →MESOappendix3y2a3g Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Su
Mesoblast Limited announced the issue of 6,856,460 ordinary fully paid securities, resulting from the exercise of previously unquoted options. The securities are set to be issued to both key management personnel and other stakeholders, contributing to the company's capital structure. This event is part of a larger strategy involving multiple option exercises over several years. No specific risks or negative events were identified in the notification.
Read more →MESOappendix3y-lco Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not
The document is an Appendix 3Y Change of Director's Interest Notice for Mesoblast Limited, detailing changes in the interests of Director Lyn Cobley. As of January 9, 2026, Cobley acquired 30,000 ordinary shares, valued at $96,000, bringing her total securities to 63,000 shares (30,000 direct and 33,000 indirect). The notice complies with ASX rules regarding disclosures of director's interests and is intended to keep the market informed.
Read more →MESO▲ +5.5%on this newsshared move
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
Mesoblast Limited reported a significant 60% increase in Ryoncil sales, reaching $35.1 million for the December quarter. The company has also secured a new $125 million financing facility, enhancing its financial position and allowing for strategic partnerships. Ryoncil, the first FDA-approved MSC therapy for pediatric patients, is set for evaluation in adult SR-aGvHD trials.
Read more →MESO▲ +5.5%on this newsshared move
ryoncilsalesde RYONCIL SALES INCREASE 60% IN DECEMBER QUARTER TO US$35.1M Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility New York, USA; January 8 and Melbourne, Australia
Mesoblast Limited reported a 60% increase in sales of its Ryoncil product, totaling $35.1 million for the December quarter. The rise in revenue reflects stronger market demand and enhances the company’s financial position, supported by a new $125 million five-year financing facility. This facility has significantly reduced the company's cost of capital and allows for greater strategic flexibility. Ryoncil is unique as it is the first FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, signaling potential for expanded market opportunities.
Read more →MESOappendix3h3y Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of
Mesoblast Limited has announced the cessation of 3,000,000 warrants (MSBAB) due to the lapse of conditional rights, as the stipulated conditions were not satisfied. This cessation, effective from January 6, 2026, affects the company's issued capital. Following this event, the total number of securities will be adjusted to reflect the changes in their capital structure. The announcement highlights potential regulatory challenges faced by the company.
Read more →MESOMesoblast Announces Changes to Board of Directors’ Leadership Roles
Mesoblast Limited announced significant changes to its Board of Directors, including the retirement of Jane Bell as Chair and the appointment of Philip Facchina as the new non-executive Chair. The changes aim to align the Board's expertise with the company's transition to a revenue-generating commercial entity. The Board also appointed Lyn Cobley as Chair of the Audit and Risk Committee.
Read more →MESOboardupdate MESOBLAST ANNOUNCES CHANGES TO BOARD OF DIRECTORS' LEADERSHIP ROLES New York, USA; January 1 and Melbourne, Australia
Mesoblast Limited has announced significant changes to its Board of Directors' leadership roles, as part of its transition into a revenue-generating commercial entity. Jane Bell will step down as Chair but remain a non-executive director, while Philip Facchina has been appointed as the new non-executive Chair. Lyn Cobley will chair the Audit and Risk Committee. The Board's goal is to enhance governance and expertise for future growth and shareholder value in light of its recent FDA approval.
Read more →MESOMesoblast Announces Changes to Board of Directors' Leadership Roles
Mesoblast Limited announced changes to its Board of Directors, including the retirement of Jane Bell as Chair and the appointment of Philip Facchina as the new non-executive Chair. These changes reflect the company's evolution toward becoming a revenue-generating entity. The adjustments also aim to enhance governance and ensure a balance of expertise within the Board, which is critical for the company's commercialization efforts. Mesoblast continues to emphasize its commitment to developing allogeneic cellular medicines for inflammatory diseases.
Read more →MESOdebtrefinancea MESOBLAST RETIRES SENIOR DEBT WITH NON-DILUTIVE, LOWER COST, FIVE-YEAR CREDIT LINE Mesoblast has option to draw down up to US$125 million by
Mesoblast Limited has announced the retirement of its senior debt through a new, non-dilutive credit line that provides financial flexibility without encumbering its assets. The company repaid part of its debt while securing a five-year facility, which allows it to draw up to $125 million. This new facility carries a reduced interest rate and offers options for future capital without early repayment penalties, enhancing the company's capability for strategic partnerships and commercialization efforts.
Read more →MESOMesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Mesoblast Limited has successfully retired its senior debt, announcing the repayment of its existing secured loan and part of a subordinated royalty facility through a new five-year credit line worth up to $125 million. This facility, provided by shareholder Dr. Gregory George, features a fixed interest rate of 8.00% and allows for substantial flexibility without encumbering material assets. The new financial terms significantly reduce the company's overall cost of capital, enabling increased potential for strategic partnerships and commercialization of its cellular medicines.
Read more →MESOapp3y-gregoryg Gregory George Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX bec
Gregory George has made changes to his interests in various securities of Mesoblast Limited. As per the Appendix 3Y on the Change of Director's Interest Notice, he acquired 4,000,000 warrants to acquire ordinary shares, which were issued as a partial commitment fee for a convertible note facility. The notice also indicates that some of Gregory's ordinary shares were converted into American Depositary Shares (ADSs) without altering his beneficial interest in the underlying shares. No securities were disposed of during this change in interests.
Read more →MESOAppendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announceme
Mesoblast Limited (ASX: MSB) has announced the issuance of 5,000,000 unquoted warrants scheduled for release on December 17, 2025. These warrants are part of a transaction previously disclosed in an Appendix 3B announcement. Each warrant can convert into one ordinary share or American Depositary Receipts (ADRs), with specific terms outlined regarding exercise price and expiration. This issuance signifies a strategic initiative aimed at enhancing the company's financial flexibility and attracting investor participation.
Read more →MESOReferences / Footnotes 1. Ramteke HD, et al. Comparative efficacy and safety of ruxolitinib and remestemcel-L in the treatment of steroid-refractory acute graft-versus-host disease: Systematic review and meta- analysis.
An independent study presented at the ASH Annual Meeting concluded that remestemcel-L significantly outperformed ruxolitinib in treating steroid-refractory acute graft versus host disease (SR-aGvHD). The analysis involved 2,732 patients, demonstrating superior outcomes in remission rates for those treated with remestemcel-L compared to ruxolitinib. Both therapies improved quality of life, but the study highlighted distinct differences in adverse events associated with each treatment. Ryoncil, the FDA-approved mesenchymal stromal cell therapy, continues to be developed for additional indications beyond pediatric SR-aGvHD.
Read more →MESOdifferences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mes
Mesoblast Limited announced its participation in the 37th Annual Healthcare Conference hosted by Piper Sandler, taking place in New York from December 2-4, 2025. CEO Silviu Itescu is set to engage in a fireside chat during the event, which will be available via live webcast. The company, recognized for its advancements in allogeneic cellular medicines, is actively working on therapies for severe inflammatory conditions and holds a significant intellectual property portfolio. However, the announcement also underscores the uncertainties tied to their forward-looking statements regarding clinical studies and market acceptance.
Read more →MESOMesoblast Participation at Piper Sandler Conference
Mesoblast Limited announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York, where CEO Silviu Itescu will conduct a fireside chat. The company focuses on developing allogeneic cellular therapies for inflammatory diseases and aims to expand its product pipeline. Their lead product, Ryoncil, is recognized as the first FDA-approved therapy of its kind for pediatric patients with steroid-refractory acute graft versus host disease. Mesoblast also boasts extensive intellectual property protections for its technologies.
Read more →MESO▲ +8.2%on this news
resultsofagm 25 November 2025 Mesoblast Limited (MSB) Results of Annual General Meeting Held 25 November 2025 In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), we advise det
Mesoblast Limited conducted its Annual General Meeting on November 25, 2025, where all proposed resolutions were successfully passed. Noteworthy outcomes included the approval of director elections and the adoption of the remuneration report with significant shareholder support. The votes demonstrated overwhelming consent for proposed options and convertible notes, reflecting confidence in the company's governance and strategy moving forward.
Read more →MESOMesoblast's Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC
Mesoblast has achieved a significant milestone with the FDA approval of Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft versus host disease in pediatric patients aged two months and older. This marks the first approval of a mesenchymal stromal cell therapy by the FDA, representing a critical advancement for the company. Since the launch, Ryoncil has seen strong market uptake and sales growth, with commercial reimbursement now covering over 260 million lives in the U.S. Furthermore, Mesoblast is planning to expand Ryoncil's use to include additional severe inflammatory conditions in both children and adults.
Read more →MESOMesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil Revenue
Mesoblast Limited announced a strong outlook during its Annual General Meeting, with a projected revenue of over $30 million from Ryoncil sales for the quarter ending December 31, 2025, marking a significant 37% increase compared to the previous quarter. The company highlighted its leadership in developing allogeneic cellular medicines for severe inflammatory conditions and emphasized its ongoing commitment to expand its product pipeline. Additionally, Mesoblast owns a substantial intellectual property portfolio, ensuring protection through 2044 in major markets.
Read more →MESOMesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
Mesoblast Limited has partnered with the Blood and Marrow Transplant Clinical Trials Network to initiate a pivotal trial for Ryoncil in adults with severe acute graft versus host disease (aGvHD) who are refractory to corticosteroids. The trial aims to assess the potential of Ryoncil, already approved for children and adolescents, in improving survival rates among adults facing poor outcomes with existing treatments. Notably, prior data indicated that 76% of patients receiving Ryoncil in an expanded access program survived by Day 100. The trial is set to begin enrollment in early 2026, targeting better therapeutic options for this high-risk patient group.
Read more →MESOMesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
Mesoblast Limited is set to meet with the FDA in December to discuss data from its Phase 3 study of rexlemestrocel-L, which shows promise in reducing opioid use in chronic low back pain patients. The treatment has demonstrated a significant ability to help patients cease opioid use over 36 months. The FDA has recognized the importance of non-opioid treatments amid the ongoing opioid crisis.
Read more →MESOfdameetingonre MESOBLAST TO MEET WITH FDA NEXT MONTH TO DISCUSS REXLEMESTROCEL-L AND OPIOID CESSATION Melbourne, Australia; November 5 and New York, USA
Mesoblast Limited announced a scheduled FDA meeting in December to discuss data on opioid reduction from its Phase 3 trial of rexlemestrocel-L in patients with chronic low back pain. The trial demonstrated over three times higher opioid cessation rates compared to saline-treated controls. Given the ongoing opioid crisis, the FDA has expressed the need for effective non-opioid pain treatments. Mesoblast is actively recruiting for a confirmatory Phase 3 trial involving 300 patients, with the aim of further establishing the efficacy of rexlemestrocel-L.
Read more →MESOappendix3y3g Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not a
Mesoblast Limited has reported a change in the interests of its director, William Burns. On October 21, 2025, Burns exercised options to acquire 120,000 ordinary shares, increasing his holding. Following this transaction, Burns holds a total of 226,250 ordinary shares and 659,651 options. The value of the shares acquired was A$157,200, reflecting a considerable investment in the company.
Read more →MESOto the Company's Post-Effective Amendment to the Registration Statement on Form S-8 (File No. 333- 267663) filed with the SEC on
Mesoblast Limited has filed its 2025 Annual Report, highlighting crucial developments such as the FDA approval of Ryoncil (remestemcel-L-rknd) for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). This achievement marks a pivotal transition from clinical development to commercialization for the company. The report emphasizes a successful launch of Ryoncil, which has already seen strong market uptake and reimbursement arrangements. Mesoblast aims to expand Ryoncil's applications and pursue further FDA approvals for additional indications in its pipeline.
Read more →MESO▼ -6.5%on this news
q1fy26appendix RYONCIL NET REVENUES INCREASE 69% IN SECOND QUARTER POST LAUNCH Activity Report for Quarter Ended
Mesoblast Limited reported a significant growth in net revenues for Ryoncil, which increased by 69% to $19.1 million in the quarter ending September 30, 2025. The rise in revenue is attributed to higher physician adoption and a new permanent J-Code for billing by Medicare and Medicaid. Additionally, the company has expanded its coverage, ensuring over 260 million US lives are insured for Ryoncil. With plans to conduct a pivotal trial for Ryoncil in adults, Mesoblast aims to broaden the medication's applicability beyond pediatric patients suffering from steroid-refractory acute graft-versus-host disease.
Read more →MESORyoncil® Net Revenues Increase 69% in Second Quarter Post Launch
Mesoblast Limited reported a 69% increase in net revenues from Ryoncil® in the second quarter following its launch. The company's CEO highlighted that the growth is driven by increased physician adoption and reimbursement support. The recent assignment of a permanent J-Code by CMS is anticipated to further enhance the product's market uptake.
Read more →MESOappendix3g Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summar
Mesoblast Limited reported an announcement regarding the issue of 2,884,341 unquoted equity securities. This issuance is part of a notification under Appendix 3G, pertaining to the conversion of existing options into fully paid ordinary shares. The exercise of these securities occurred following the scheduled timelines, maintaining regulatory compliance. The detailed breakdown of these transactions indicates careful management of investor relations and capital structure.
Read more →MESOryoncilsalesup RYONCIL REVENUES INCREASE 66% IN SECOND QUARTER POST LAUNCH Melbourne, Australia
Mesoblast Limited announced a 66% increase in gross revenues from Ryoncil sales, reaching US$21.9 million for the quarter ending September 30, 2025. This growth reflects strong market adoption and positive reimbursement trends from both commercial and government payers. The recent assignment of a permanent J-Code by CMS is anticipated to further enhance Ryoncil's market adoption. Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, targets steroid-refractory acute graft-versus-host disease in children under 12.
Read more →MESO▲ +8.2%on this newsshared move
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
Mesoblast Limited announced that Ryoncil® (remestemcel-L-rknd) has received a permanent J-Code from CMS, effective October 1, 2025. This coding will streamline billing and reimbursement processes, improving access for pediatric patients with steroid-refractory acute graft-versus-host disease. The J-Code is expected to influence commercial payers' coverage systems as well.
Read more →MESO▲ +8.2%on this newsshared move
ryoncilcmsj-co RYONCIL RECEIVES J-CODE FROM MEDICARE & MEDICAID SERVICES (CMS) FACILITATING REIMBURSEMENT AND BROADER PATIENT ACCESS Melbourne, Australia
Mesoblast Limited announced that Ryoncil (remestemcel-L-rknd) has received a permanent J-Code from the United States Medicare & Medicaid Services, effective October 1, 2025. This coding allows for standardized billing and reimbursement, significantly enhancing patient access to this critical treatment for steroid-refractory acute graft-versus-host disease in pediatric patients. Ryoncil is distinguished as the first mesenchymal stromal cell product approved by the FDA for this indication, marking a significant achievement for the company and its commercialization efforts. Healthcare providers can begin using this J-Code immediately for claims.
Read more →MESOactual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We m
Mesoblast Limited has reaffirmed that its allogeneic cell therapy products, particularly Ryoncil, are manufactured from U.S. donors and are exempt from tariffs. Ryoncil, the only FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients, is underscored by a robust global patent portfolio. The company is also pursuing further developments and potential approvals for additional inflammatory diseases while maintaining strategic commercial partnerships across key international markets.
Read more →MESOMesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
Mesoblast Limited has confirmed that its allogeneic cell therapy products are manufactured in the U.S. from U.S. donors and are not subject to tariffs. The company's Ryoncil® is the only FDA-approved therapy for steroid-refractory acute graft versus host disease in pediatric patients. Mesoblast continues to develop additional therapies for inflammatory diseases and has a robust intellectual property portfolio.
Read more →MESOSuccessful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
Mesoblast Limited announced the successful commercial launch of Ryoncil® at global healthcare conferences. The product, which treats steroid-refractory acute graft versus host disease in children, has shown strong initial sales. The company plans to expand Ryoncil® into adult indications and inflammatory bowel disease, alongside key milestones for its second-generation product.
Read more →MESOlevels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigatio
Mesoblast Limited has successfully launched Ryoncil, a mesenchymal stromal cell therapy approved by the FDA for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The product's launch was featured at notable global healthcare conferences, where CEO Silviu Itescu discussed the strong initial sales performance and plans to extend the therapy's use to adult patients and new indications. The company is also working towards key Phase 3 milestones for its second-generation product, Rexlemestrocel-L.
Read more →MESOdrggeorgeappen Gregory George Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX bec
Gregory George, a director of Mesoblast Limited (MESO), has reported a substantial change in director's interests involving the acquisition of 9,640,072 shares and 325,901 American Depositary Shares (ADS). This transaction, valued at approximately $18.85 million, signals a strong personal investment by the director. Prior to this, he held 19,350,005 ordinary shares and various warrants. The update pertains to compliance with ASX listing rules regarding changes in director's securities holdings.
Read more →MESOMesoblast Enters Into Option To Issue US$50 Million Convertible Notes
Mesoblast Limited has entered into agreements to issue up to $50 million in unsecured convertible notes, subject to shareholder approval. The funding aims to optimize the company's capital structure and support ongoing growth opportunities. The notes can be converted into shares at a premium, and investors will receive warrants as part of the deal.
Read more →MESO▼ -13.3%on this newsshared move
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Mesoblast Limited has achieved a significant milestone with the FDA approval of Ryoncil®, the first approved mesenchymal stromal cell product in the U.S. for treating steroid-refractory acute graft-versus-host disease in pediatric patients. The product was launched commercially shortly after approval, and the company is expanding its coverage and access programs. Future plans include seeking additional indications and conducting pivotal trials to extend Ryoncil®'s use in adults and for inflammatory bowel diseases.
Read more →MESO▼ -13.3%on this newsshared move
Chronic low back pain (CLBP) $10 billion addressable market. Additional potential multi-billion-dollar opportunities from existing and future product pipeline based on existing technology platforms. Competitive Advantage
Mesoblast Limited achieved FDA approval for Ryoncil, the first and only mesenchymal stromal cell product approved for pediatric patients with steroid-refractory acute graft-versus-host disease. Following its commercial launch, the company reported impressive financial results with a 191% increase in revenue from cell therapy products. Looking ahead, Mesoblast is focused on expanding Ryoncil's indications and plans to initiate trials for additional therapies targeting chronic low back pain and other conditions. The company also highlighted a strong balance sheet to support ongoing growth and its product pipeline.
Read more →MESOFor more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media - Global Allison Worldwide Emma Neal T: +1 603 545 4843 E: emma.neal@allisonworldwide.com Media - Australia
Mesoblast Limited announced that it will host a webcast to review its financial results and operational highlights for the year ending June 30, 2025. The event is scheduled for August 29, 2025, in Melbourne and will be accessible to the public online. The company focuses on developing allogeneic cellular medicines for inflammatory diseases and maintains a strong intellectual property portfolio to aid its commercial objectives. Mesoblast's flagship product Ryoncil, approved for treating a specific inflammatory condition in pediatric patients, underscores its commitment to innovation in this field.
Read more →MESO▲ +26.6%on this news
Successful Commercial Launch of Ryoncil®
Mesoblast Limited has successfully launched Ryoncil®, the first FDA-approved mesenchymal stromal cell product for treating steroid-refractory acute graft-versus-host disease in children. The product became available on March 28, 2025, and has generated positive revenue in its first quarter. The company is optimistic about ongoing commercial activities and the onboarding of transplant centers.
Read more →MESOAppendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 2 / 4 Part 1 - Announcement Details 1.1 Name of +Entity MESOBLAST LIMITED We (the entity named above) provide th
Mesoblast Limited has announced the cessation of 483,254 securities identified under the ASX code MSBAI, due to the lapse of conditional rights, as the necessary conditions for those rights have not been satisfied. This notification comes on July 14, 2025, and reflects the company's efforts to update its issued capital structure. Following this cessation, the total number of various classes of securities issued by the company will be adjusted accordingly.
Read more →MESO▲ +11.3%on this news
Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure
Mesoblast has aligned with the FDA regarding the Biologics License Application for Revascor in treating ischemic heart failure with reduced ejection fraction. The agreement follows a successful Type B meeting where the FDA suggested that prior study results could support accelerated approval. Mesoblast plans to submit the application by the end of this year, focusing on patients with end-stage heart failure who have a left ventricular assist device. This alignment demonstrates progress in bringing their innovative therapies to market, as the company also develops additional treatments for various inflammatory conditions.
Read more →MESOIn July, Mesoblast held a Type B meeting with FDA for Ryoncil to discuss a pivotal trial in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN),
Mesoblast Limited has reported a successful commercial launch of Ryoncil, generating gross revenue of $13.2 million in its first quarter. The company has been onboarding over 25 transplant centers, aiming to complete onboarding at 45 priority centers for pediatric SR-aGvHD treatment. Ryoncil recently received FDA's seven-year orphan-drug exclusivity, ensuring no competitive MSC products can enter the market for this indication. Additionally, Mesoblast is preparing to extend Ryoncil’s label to adult patients and enhance insurance coverage nationwide.
Read more →MESOMesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD
Mesoblast provided an update on its progress with the FDA regarding the accelerated approval of Revascor® for ischemic heart failure and the extension of Ryoncil®'s label to adults with steroid refractory acute graft versus host disease. A Type B meeting was held with the FDA to align on the Biologics License Application for Revascor®, while an upcoming meeting aims to discuss pivotal trials for Ryoncil®. The commercial launch of Ryoncil® exceeded expectations, with significant hospital onboarding and insurance coverage reported.
Read more →MESOryoncilfdaexcl FDA PROVIDES SEVEN YEARS OF ORPHAN-DRUG EXCLUSIVE APPROVAL FOR RYONCIL Melbourne, Australia; May 15 and New York, USA
Mesoblast has announced that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan-drug exclusive approval for Ryoncil (remestemcel-L) to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older. This exclusivity prohibits the approval of competing mesenchymal stromal or stem cell products for the same indication during this period. Additionally, Mesoblast holds biologic exclusivity preventing bio-similars until December 2036, alongside a robust intellectual property portfolio ensuring market protection against competitors until at least 2044.
Read more →MESOheld under Mesoblast's Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR. In a Type B meeting last year, FDA provided guidance to Mesoblast that the company was eligible to file for accelerated appr
Mesoblast Limited has announced significant progress, including the U.S. commercial launch of Ryoncil for treating acute graft versus host disease in children. The company has a robust cash position, enhancing its capacity to expand Ryoncil's indications to other serious conditions. Upcoming discussions with the FDA regarding Revascor suggest a potential for accelerated approval based on existing clinical data. Additionally, Mesoblast is actively enrolling patients for a Phase 3 trial of its product for chronic low back pain, indicating ongoing development in multiple therapeutic areas.
Read more →MESOMesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Meso
Mesoblast announced the appointment of Lyn Cobley to its Board of Directors on April 28, 2025. Cobley brings over 30 years of experience in finance, having held prominent positions in various major banks. Her appointment follows the FDA approval of Ryoncil, indicating a pivotal moment for the company. Mesoblast is focusing on ramping up commercialization and exploring additional indications for its therapies, while maintaining an extensive intellectual property portfolio.
Read more →MESOMesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
Mesoblast has appointed Lyn Cobley to its Board of Directors. Cobley, a seasoned leader in financial services, brings over 30 years of experience from various high-profile banking positions. Her appointment follows the recent FDA approval of Mesoblast's therapy, Ryoncil, with plans for further commercialization and development of additional treatments for inflammatory diseases. The company aims to expand its impact in the allogeneic cell therapy industry, focusing on significant upcoming milestones.
Read more →MESO▲ +6.8%on this newsshared move
Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2 3476-9185-3625, v. 1 Number disposed Expiry of put option over 50,000 ADS, each representing 10 ordinary
Mesoblast Limited announced a Change of Director's Interest Notice regarding Gregory George. The notice details changes in his shareholdings, including the acquisition of 50,000 American Depositary Shares (ADS) following the expiry of a put option. After the change, the total number of ADS held increases, reflecting ongoing confidence in the company's operations. No securities were traded during a closed period. The valuation of the shares acquired amounts to approximately US$521,917.
Read more →MESOMesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives
Mesoblast has announced an extension of coverage for its FDA-approved therapy, Ryoncil (remestemcel-L), to 104 million lives in the US, achieved through both government and commercial payers. This expansion includes comprehensive Medicaid coverage in 37 states, providing significant access for patients with steroid-refractory acute graft versus host disease. Ryoncil's approval marks a milestone as the first mesenchymal stromal cell therapy, with further development plans in place for additional inflammatory diseases. Mesoblast continues to leverage its proprietary cell therapy technologies across various indications.
Read more →MESOMesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
Mesoblast announced that its allogeneic cell therapy products, including Ryoncil® and Revascor®, are designated as U.S. origin and will not incur tariffs. This designation aligns with regulations that could positively influence the company's commercial opportunities. Mesoblast continues to advance its proprietary cell therapy technologies in treating severe inflammatory diseases, bolstered by a robust intellectual property portfolio and strategic partnerships worldwide.
Read more →MESOMesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure
Mesoblast recently requested a Type B meeting with the FDA to discuss the accelerated approval pathway for Revascor in treating ischemic heart failure. Following prior guidance from the FDA, they aim to clarify issues regarding manufacturing controls and the design of a confirmatory trial. The meeting aligns with the FDA's RMAT designation for Revascor, and if successful, could expedite availability for patients. Mesoblast continues to lead in allogeneic cellular medicines, focusing on inflammatory diseases and establishing partnerships globally.
Read more →MESOCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainti
Mesoblast's recent presentation emphasizes the complexities and uncertainties inherent in their forward-looking statements regarding future financial performance and product developments. The company highlights its leadership in allogeneic cellular medicines, particularly the FDA-approved therapy Ryoncil for children with steroid-refractory acute graft versus host disease. However, Mesoblast also cautions stakeholders about the risks associated with clinical trials, regulatory approvals, and reliance on collaborators, all of which could materially impact their business outcomes.
Read more →MESOryoncilpublica RYONCIL PRODUCT INFORMATION NOW AVAILABLE IN ALL FOUR MAJOR DRUG PRICING COMPENDIA IN UNITED STATES Melbourne, Australia; March 14 and New York, USA
Mesoblast Limited announced that Ryoncil's product information is now accessible in all four major drug pricing compendia in the United States. This follows the approval of a revised label by the FDA, which includes updated manufacturing details and eight new kits with distinct National Drug Codes (NDC) for varying patient weight-dosage needs. The development is expected to enhance product ordering and treatment customization for healthcare providers and patients. Additionally, Mesoblast continues to explore further therapeutic applications for Ryoncil and its other products.
Read more →MESOresearch and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its
Mesoblast Limited announced that its CEO, Silviu Itescu, will present at the ISCT North America Virtual Town Hall on March 12, 2025. The presentation will highlight RYONCIL, the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease. Mesoblast is also developing additional therapies for various inflammatory conditions and has established manufacturing processes for off-the-shelf cellular medicines. The company holds a robust patent portfolio that provides commercial protection into the future.
Read more →MESOMesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
Mesoblast Limited announced that its CEO, Silviu Itescu, will deliver a featured presentation on RYONCIL, the first FDA-approved mesenchymal stromal cell therapy, at the ISCT North America Virtual Town Hall. The presentation highlights the company's leadership in developing allogeneic cellular medicines for severe inflammatory diseases. Mesoblast is also expanding its therapeutic portfolio beyond pediatric applications of RYONCIL, and actively pursuing other indications, which underlines its commitment to innovation in cellular medicine. The presentation can be accessed online on the ISCT's official platform.
Read more →MESOmaterial and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research a
Mesoblast Limited announced that it has been added to the S&P/ASX 200 Index, effective prior to the commencement of trading on March 6, 2025. This acceptance indicates the company's significant market presence and recognition as a leader in allogeneic cellular medicines. Mesoblast's RYONCIL therapy is notable as the first FDA-approved mesenchymal stromal cell therapy. Despite the positive development, the company acknowledges various risks and uncertainties related to its future performance and regulatory approvals.
Read more →MESO▼ -7.7%on this newsshared move
Mesoblast Added to S&P/ASX 200 INDEX
Mesoblast Limited has been added to the S&P/ASX 200 Index, effective March 6, 2025. This index is a prominent benchmark in Australia, highlighting the performance of the largest publicly listed companies. The inclusion reflects Mesoblast's leadership in developing allogeneic cellular therapies for serious inflammatory diseases. RYONCIL, its FDA-approved treatment for pediatric patients, exemplifies the company's innovative capabilities in the biopharmaceutical sector.
Read more →MESO▲ +10.4%on this news
as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Dr. George will not be a
Mesoblast Limited has announced the upcoming availability of Ryoncil, the first FDA-approved therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). The treatment, which has shown promising survival rates, will be fully operational in U.S. transplant centers soon. The company reported a strong cash position of $38 million and additional funding of approximately $200 million after a global private placement. Future plans include further trials utilizing Ryoncil for related inflammatory diseases, indicating a strategic expansion of its product pipeline.
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2024 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
Mesoblast Limited reported a decline in revenue and an increase in losses for the half-year ended December 31, 2024. Revenue from ordinary activities fell by 7%, while the net loss attributable to members surged by 47%, amounting to $47,934,000. The company reported negative net tangible assets per security, reflecting a liability of 7.59 cents. No dividends have been proposed for this period, indicating financial challenges.
Read more →MESOMesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
Mesoblast Limited has announced the imminent availability of Ryoncil, an FDA-approved therapy for steroid-refractory acute graft versus host disease in pediatric patients. The treatment boasts a promising overall response rate of 70% and significant survival outcomes. Additionally, the company is expanding its reach through collaborations with leading pediatric transplant centers across the U.S. to ensure broad access to this life-saving product. Mesoblast's financial position has strengthened, enabling continued development and commercialization efforts for Ryoncil and other therapies.
Read more →MESOand patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial
Mesoblast Limited has appointed Dr. Gregory George, a significant shareholder and experienced operator, to its Board of Directors. His skills are expected to support the company's transition into a more efficient commercial entity. Known for developing allogeneic cellular medicines, Mesoblast has a strong patent portfolio and is committed to its innovative therapies. However, the company acknowledges potential risks and uncertainties related to its forward-looking statements and product commercialization efforts.
Read more →MESOMesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additio
Mesoblast Limited has announced that its FDA-approved product Ryoncil (remestemcel-L) for treating steroid-refractory acute graft-versus-host disease in pediatric patients is being highlighted at the 2025 Transplantation & Cellular Therapy Tandem Meetings in Hawaii. The company aims to leverage this platform to educate healthcare providers and discuss scientific results associated with Ryoncil. Additionally, Mesoblast is committed to developing further cell therapies for various inflammatory diseases, including adult SR-aGvHD and chronic low back pain.
Read more →MESOOther Fees to Non-Executive Directors were US$295,803, consulting payments to Non-Executive Directors were US$80,602 and salary payments to full-time Executive Directors were US$231,552, detailed in Item 6 of the Appendi
Mesoblast Limited reported significant advancements in its cellular therapies, with the FDA approving Ryoncil, the first MSC therapy for steroid-refractory acute graft versus host disease in children. The company has established a distribution network and is actively enrolling patients for ongoing trials of rexlemestrocel-L for chronic low back pain. Additionally, Mesoblast raised AU$260 million to enhance its operations and expand clinical trial sites. These developments highlight the company’s commitment to innovating in the treatment of severe inflammatory conditions.
Read more →MESOAppendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 2 / 5 Part 1 - Entity and announcement details 1.1 Name of entity MESOBLAST LIMITED We (the entity named above)
Mesoblast Limited has submitted an application for the quotation of 97,680,000 ordinary fully paid securities under the ASX code MSB. This announcement was made on January 17, 2025, and is part of a strategic effort linked to a prior transaction outlined in an Appendix 3B. The securities are set to be issued for a cash consideration valued at AUD 2.50 each, indicating the company's intent to enhance its capital structure. Following this issuance, the company's total quoted securities will amount to over 1.26 billion.
Read more →MESOMESOBLAST RAISES NEW CAPITAL FOR COMMERCIAL LAUNCH OF RYONCIL Not for release to US wire services or distribution in the United States Melbourne, Australia; January 14 and New York, USA
Mesoblast Limited announced the successful completion of a global private placement, raising A$260 million (approximately US$160 million) to fund the commercial launch of Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The funds will also accelerate the second Phase 3 study for chronic low back pain and expand manufacturing activities. The company is positioned to enhance production capabilities to meet the expected demand for its therapies, backed by solid support from its shareholders.
Read more →MESO▲ +17.8%on this news
Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change 5,451,434 ordinary shares (including 41,162 ADS - each ADS represents
The article reports on a Change of Director's Interest Notice issued by Mesoblast Limited regarding Dr. Eric Rose. As of December 13, 2024, Dr. Rose has increased his holdings to 5,451,434 ordinary shares, including 41,162 American Depositary Shares (ADSs). This change includes a significant acquisition of 5,039,814 ordinary shares, which was valued at approximately A$1.5 million. The acquisition occurred through a share placement approved by shareholders at the upcoming 2024 AGM.
Read more →MESO▼ -12.7%on this newsshared move
(including any future decision that the FDA may make on the BLA for remestemcel-L for pediatric patients with SR-aGVHD), manufacturing activities and product marketing activities, if any; the commercialization of Mesobla
Mesoblast Limited has announced its inclusion in the Nasdaq Biotechnology Index, effective December 23, 2024. This recognition highlights Mesoblast's leadership in developing allogeneic cellular medicines for inflammatory diseases. The company boasts a robust pipeline of product candidates and has formed strategic partnerships for commercialization in key markets. Its innovative technology platform is designed to address severe inflammatory conditions, with ongoing developments for pivotal treatment options.
Read more →MESO▼ -12.7%on this newsshared move
What is RYONCIL (remestemcel-L) RYONCIL is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatri
Mesoblast's RYONCIL (remestemcel-L) has received FDA approval as the first mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older. In a Phase 3 trial, 70% of participants achieved a favorable response by Day 28, marking a significant advancement in treatment options for this severe condition. The therapy is also being explored for potential use in other inflammatory diseases. Mesoblast plans to continue working with the FDA for further product approvals.
Read more →MESO▲ +36.8%on this newsshared move
Mesoblast’s RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
Mesoblast has announced that the FDA has approved RYONCIL (remestemcel-L), marking it as the first-ever mesenchymal stromal cell (MSC) therapy in the U.S. for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). In a Phase 3 study, 70% of patients achieved an overall response by Day 28, significantly improving prognosis for this life-threatening condition. The approval allows RYONCIL to be administered at transplant centers across the U.S., providing a new treatment option for children and families facing this severe illness.
Read more →MESOMesoblast to be Added to Nasdaq Biotechnology Index
Mesoblast Limited announced its addition to the Nasdaq Biotechnology Index as part of the index's annual reconstitution, effective December 23, 2024. This inclusion reflects the company's status as a leader in allogeneic cellular medicines for inflammatory diseases. Mesoblast is known for its late-stage product candidates and has established a significant global intellectual property portfolio. The company also holds various partnerships in Europe and China, which enhance its position in the biotech industry.
Read more →MESOAbout Hypoplastic Left Heart Syndrome (HLHS) HLHS is a severe congenital heart disease in which the left side of the heart does not fully develop and effective pumping of oxygenated blood by the left ventricle to the res
Mesoblast Limited announced that the FDA has granted its therapy Revascor (rexlemestrocel-L) the Regenerative Medicine Advanced Therapy (RMAT) designation for use in children with hypoplastic left heart syndrome (HLHS). This designation follows the therapy's previous recognition as a Rare Pediatric Disease and Orphan Drug. Initial trial results indicate that Revascor may significantly enhance left ventricular growth in children suffering from HLHS, which is crucial for potential surgical success. This recognition from the FDA suggests an expedited path towards potential approval for treating this serious condition.
Read more →MESOAbout Revascor (rexlemestrocel-L) in Heart Disease REVASCOR is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells (MPC) and is being developed as an immunomodulatory therapy to a
Mesoblast Limited announced positive results from the Phase 3 DREAM-HF trial for Revascor (rexlemestrocel-L), an allogeneic cell therapy targeting ischemic heart failure with inflammation. According to findings published in the European Journal of Heart Failure, a single injection of Revascor improved survival and reduced major adverse cardiovascular events in high-risk patients. The company is exploring pathways for regulatory approval, particularly in those with end-stage heart failure. Given the high mortality rates among chronic heart failure patients, these results may offer a promising new treatment option.
Read more →MESO▲ +5.9%on this news
Appendix 3Z Final Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Z Page 2 11/3/2002 Part 2 - Director's relevant interests in securities of which the director is not the registered holder Note:
Mesoblast Limited has issued its final Director's Interest Notice, providing details about Joseph Swedish's interests in the company's securities. The notice includes information about options held by Swedish and additional options to be issued pending shareholder approval at the 2024 AGM. It also states Swedish's beneficial ownership of American Depositary Shares held in a trust. This report follows regulatory requirements for disclosures regarding director interests.
Read more →MESORevascor (Rexlemestrocel-L) for Pediatric Congenital Heart Disease - Hypoplastic Left Heart Syndrome Earlier this year, FDA granted Mesoblast's second generation allogeneic, STRO3-immunoselected, and industrially manufac
Mesoblast Limited reported significant advancements in its clinical programs, particularly for REVASCOR, which received both Rare Pediatric Disease and Orphan-Drug designations from the FDA for hypoplastic left heart syndrome. Trial results indicated positive outcomes in heart function in children receiving REVASCOR. The company is also actively preparing for the commercial launch of RYONCIL, having filed a Biologics License Application in the U.S. with expectations for a decision by January 2025. Additionally, Mesoblast has implemented a convertible note financing strategy to ensure funds for its upcoming projects.
Read more →MESOThe convertible notes will be unsecured and be subordinated to the Company's two existing secured financing facilities. The conversion price is subject to adjustment mechanisms in the event of future share issues, capita
Mesoblast Limited has announced a convertible note agreement with its largest shareholder, allowing it to issue up to $50 million to support the launch of its lead product, Ryoncil, pending FDA approval. This funding option is designed to bolster the company's commercial strategy for Ryoncil in treating children with steroid-refractory acute graft versus host disease. The agreement emphasizes a committed approach to market access and provider engagement, targeting key medical centers for product introduction. However, the convertible notes are unsecured, presenting additional risks regarding the company's financial structure as it seeks regulatory approval.
Read more →MESO▲ +7.5%on this news· ran to +26% by day 3shared move
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
Mesoblast announced a convertible note subscription agreement allowing for the issuance of up to US$50 million, conditional upon FDA approval of its lead product candidate, Ryoncil, for treating children's steroid-refractory acute graft versus host disease. This funding aims to facilitate the company's commercial strategy post-approval. CEO Silviu Itescu acknowledged the support from major shareholder Gregory George, underscoring the importance of being well-capitalized for the product launch. Pre-launch activities have already commenced, with plans for targeted hiring and payer engagement.
Read more →MESOo Ongoing KOL engagement with greatest experience using RYONCIL at highest volume centers o Non-promotional activities including profiling high-volume centers, education on disease awareness & unmet needs, and payer enga
Mesoblast Limited has reported significant progress in its operational update and financial results for the fiscal year ending June 30, 2024. The company has resubmitted its Biologics License Application for RYONCIL and expects feedback from the FDA by January 7, 2025. Active patient enrollment is underway in clinical trials for its other products, including new treatments for chronic low back pain and pediatric congenital heart disease. Moreover, Mesoblast is preparing a targeted commercial strategy to ensure successful market entry for RYONCIL upon approval.
Read more →MESOMesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
Mesoblast Limited has reported its financial results and operational updates for FY2024, highlighting significant interactions with the FDA regarding its products. The company successfully resubmitted the Biologics License Application for Ryoncil for treating SR-aGVHD in children and anticipates a decision by January 7, 2025. Multiple Phase 3 trials are currently underway, including studies for inflammatory back pain and chronic heart failure. Additionally, Mesoblast received key designations from the FDA, enhancing its strategic positioning for future approvals.
Read more →MESO▼ -7.1%on this news
Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Persistent Inflammation FDA informed Mesoblast that it supports an accelerated approval pathway for its second generation allogeneic, immunoselected, and i
Mesoblast Limited announced that the FDA supports an accelerated approval pathway for its product Revascor (rexlemestrocel-L), intended for patients with end-stage ischemic heart failure and reduced ejection fraction. The Phase 3 trial demonstrated significant benefits including reduced inflammation and improved heart function. The company is also preparing for the commercial launch of Ryoncil, which is under review for treating pediatric patients with acute graft versus host disease. Overall, Mesoblast is achieving positive milestones in its product development pipeline.
Read more →MESO▼ -6.7%on this news· ran to -19% by day 3
In addition, results of a 4-year survival study performed by the Center for International Blood and Marrow Transplant Research (CIBMTR) on 51 evaluable patients with SR-aGVHD who were enrolled in the Phase 3 trial, demon
Mesoblast Limited announced that the FDA has accepted its resubmission of the Biologics License Application for Ryoncil (remestemcel-L) to treat children with steroid-refractory acute graft versus host disease (SR-aGVHD). This therapy, if approved, would be the first allogeneic off-the-shelf cellular medicine in the United States for this patient group. Recent trials indicated significant survival benefits at Day 28 and beyond, with higher overall response rates compared to existing treatments. Mesoblast anticipates an FDA decision by January 7, 2025.
Read more →MESOsurvival at 1 year, 51% at 2 years, and 49% survival through 4 years in children with expected 2 year survival of just 25-38% using best available therapy.2-4 About Steroid-Refractory Acute Graft Versus Host Disease Acut
Mesoblast Limited has resubmitted its Biologics License Application (BLA) for Ryoncil to the FDA for the treatment of children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). The resubmission follows FDA guidance indicating that available clinical data supports the application. The Phase 3 study demonstrated a significant increase in survival rates and overall response compared to current standard therapies. The BLA is expected to undergo review within two to six months following acceptance.
Read more →MESOMesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Mesoblast Limited has resubmitted its Biologics License Application (BLA) to the FDA for Ryoncil (remestemcel-L), targeting treatment of children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). This follows positive feedback from the FDA regarding the Phase 3 clinical data supporting the application. The resubmission also aims to address remaining Chemistry, Manufacturing, and Control items. Remestemcel-L has received Fast Track and Priority Review designations, highlighting its potential significance in improving survival outcomes in this patient group.
Read more →MESOintellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual
Mesoblast Limited announced that it will submit a Biologics License Application for Ryoncil (remestemcel-L) to the FDA for treating children with steroid-refractory acute graft versus host disease. The company emphasizes its leadership in developing allogeneic cellular medicines and its robust intellectual property portfolio. Additionally, Mesoblast has commercial partnerships in Europe and China for certain assets, highlighting its international presence. While the company expresses optimism, it acknowledges various risks associated with future clinical and regulatory processes.
Read more →MESOMesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week
Mesoblast Limited has announced its intent to file a Biologics License Application (BLA) with the FDA for its product Ryoncil (remestemcel-L), aimed at treating pediatric patients with steroid-refractory acute graft versus host disease. The company emphasizes its leadership in developing allogeneic cellular medicines and highlights the robustness of its intellectual property portfolio. While the filing marks a significant step forward, the company acknowledges inherent risks and uncertainties associated with regulatory approval processes and market acceptance of stem cell therapies.
Read more →MESOthe initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successf
Mesoblast Limited provided an update on its product candidates at the Bell Potter Emerging Leaders Conference. The company is preparing to resubmit its Biologics License Application (BLA) for Ryoncil, targeting treatment for steroid-refractory acute graft versus host disease, with potential FDA approval expected in the latter half of 2024. Additionally, Mesoblast is advancing its Phase 3 programs for heart failure and chronic low back pain, with feedback from the FDA indicating a possible accelerated approval process for its heart failure product. The company holds a strong intellectual property position in the US, with patents extending through 2043.
Read more →MESOMesoblast Corporate Presentation at Investor Conference
Mesoblast Limited (NASDAQ: MESO) provided a corporate update at the Bell Potter Emerging Leaders Conference, sharing plans to resubmit a Biologics License Application (BLA) for remestemcel-L aimed at treating steroid-refractory acute graft versus host disease. The company has received feedback from the FDA regarding an accelerated approval pathway for its heart failure product Revascor, which is currently in Phase 3 trials. Additionally, Mesoblast highlighted its robust intellectual property portfolio and ongoing global partnerships in Europe and China for certain product candidates.
Read more →MESOAppendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation US$151,20
Dr. Eric Rose, a director of Mesoblast Limited, has made a significant change in his interest in the company's securities. He acquired an additional 19,734 American Depositary Shares (ADS), bringing his total holdings to 41,162 ADS along with 4,330,765 options. This transaction took place on May 8, 2024, for an estimated value of $151,207.83. Notably, Dr. Rose is also set to receive over 5 million ordinary shares pending shareholder approval at the upcoming Annual General Meeting.
Read more →MESOAppendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change 4,330,765 options 21,428 ADS *Please note, Dr Rose will be issued 5,0
Mesoblast Limited announced a change in director's interest notice regarding Dr. Eric Rose, who has acquired 21,428 ADS. This acquisition was part of an on-market share purchase valued at approximately US$142,318.35. Additionally, Dr. Rose is set to be issued 5,039,814 ordinary shares pending shareholder approval at the 2024 Annual General Meeting. These changes showcase a continued commitment from the director despite the uncertainty surrounding shareholder approval.
Read more →MESO▲ +9.2%on this news· ran to +21% by day 3shared move
Cardiovascular - Pediatric Congenital Heart Disease During the quarter FDA granted Mesoblast a Rare Pediatric Disease (RPD) Designation for Revascor (rexlemestrocel-L) following submission of results from the randomized
Mesoblast Limited announced positive developments in its product pipeline, including receiving a Rare Pediatric Disease Designation from the FDA for Revascor in treating hypoplastic left heart syndrome. The company aims to resubmit its Biologics License Application for remestemcel-L to address pediatric acute graft versus host disease, with expectations for approval in the latter half of 2024. Additionally, Mesoblast expressed intent to pursue accelerated approval for Revascor given positive results from its studies, reflecting their commitment to addressing significant healthcare needs.
Read more →MESO▲ +6.8%on this news· ran to +18% by day 3
appendix3y-cha Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not
Mesoblast Limited has submitted a Change of Director's Interest Notice to the ASX regarding Jane C. Bell's recent acquisition of ordinary shares. On April 12, 2024, Bell acquired 233,918 ordinary shares, increasing her indirect holdings to 543,441 shares. This acquisition reflects a transaction valued at approximately $199,999.89. The report follows ASX rules for disclosing changes in director interests.
Read more →MESO▼ -9.3%on this newsshared move
appendix2a-app Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 7 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date
Mesoblast Limited has announced an application for the quotation of 1,072,363 ordinary fully paid securities on the Australian Securities Exchange. This new issuance is part of an employee incentive scheme, indicating the company's strategy to align employee interests with shareholder value. The announcement was made on April 16, 2024, and reflects a proactive approach in expanding its capital structure. The company's efforts in engaging employees through share options may enhance overall organizational performance.
Read more →MESOappendix3h-not Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date
Mesoblast Limited announced the cessation of 80,000 options (MSBAI) due to the lapse of conditional rights, as the conditions for these securities were not met or are no longer achievable. This notification highlights a significant reduction in their available equity, which may impact future funding and investment opportunities. The announcement may raise concerns regarding the company's ongoing financial health and operational stability. The issued capital of the entity will be updated following this cessation.
Read more →MESOfdanotifiescli {00876702} UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) NOTIFIES MESOBLAST THAT AVAILABLE CLINICAL DATA FROM PHASE 3 TRIAL APPEAR SUFFICIENT TO SUPPORT BLA SUBMISSION FOR REMESTEMCEL-L IN CHILDREN WITH S
The FDA has notified Mesoblast that the available clinical data from its Phase 3 trial appears sufficient to support a Biologics License Application (BLA) submission for remestemcel-L. This treatment is aimed at pediatric patients suffering from steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast's CEO expressed gratitude towards the FDA for their guidance, indicating a high level of confidence in proceeding with the resubmission, which is planned for the next quarter. The company continues to develop cellular therapies for various severe inflammatory conditions, bolstered by a strong intellectual property portfolio.
Read more →MESOappendix3b Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement 14/3/
Mesoblast Limited announced a proposed issuance of 5,039,814 ordinary fully paid securities, expected to be conducted as a placement. This announcement is part of their strategy to secure funding and is scheduled for realization on December 30, 2024. The share price is set at AUD 0.30, reflecting a potential opportunity for investors to participate in the company's future growth.
Read more →MESO▼ -8.3%on this news
MESOBLAST SUCCESSFULLY COMPLETES PLACEMENT AND ACCELERATED ENTITLEMENT OFFER Melbourne, Australia; March 14 and New York, USA
Mesoblast Limited has successfully completed its pro-rata accelerated entitlement offer, raising a total of A$97 million. The funding was primarily supported by existing major shareholders, including an additional investment of A$1.5 million from Dr. Eric Rose, the Chief Medical Officer. Mesoblast is advancing its proprietary allogeneic cellular therapies aimed at treating severe inflammatory diseases and has established partnerships for certain products in Europe and China. The company holds a robust intellectual property portfolio that enhances its competitive position in the market.
Read more →MESO▼ -5.7%on this news
Mesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2023 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
Mesoblast Limited has reported a half-year financial loss for the period ending December 31, 2023. Revenues declined slightly while the net loss attributable to members increased by 21%. The company's ability to continue its operations is uncertain due to substantial cash outflows and the need for additional funding in the coming months. As the company navigates these financial challenges, no dividends have been proposed or declared.
Read more →MESOMesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Mesoblast Limited reported operational updates and financial results for the half-year ended December 31, 2023. The company highlighted its productive engagement with the FDA regarding its lead programs, including Ryoncil for acute graft-versus-host disease and Revascor for heart conditions, as well as their ongoing efforts to reduce cash usage and strengthen their financial position. Mesoblast is poised for further discussions with the FDA regarding approval pathways for their therapies, supported by promising clinical data. Additionally, they reported a reduction in net cash usage compared to previous periods.
Read more →MESOhy1fy24results MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL UPDATE FOR HALF-YEAR ENDED DECEMBER 31, 2023 Melbourne, Australia; February 29 and New York, USA
Mesoblast Limited reported its financial results and operational updates for the half-year ended December 31, 2023, highlighting significant FDA engagement regarding its lead products, Ryoncil and Revascor. The company achieved a reduction in cash usage and strengthened its balance sheet while navigating regulatory discussions. Additionally, Mesoblast received Rare Pediatric Disease and Orphan Drug Designations for Revascor, reflecting progress in its clinical trials for life-threatening conditions. The updates were accompanied by caution regarding ongoing operational costs and the dependence on successful FDA approvals.
Read more →MESOimmediate surgery after birth, the prognosis is dismal with HLHS overall being responsible for 25% to 40% of all neonatal cardiac mortality.2 In the longer term, surgery that creates a two-ventricle series circulation wi
Mesoblast Limited announced that the FDA has granted its therapy Revascor (rexlemestrocel-L) Orphan-Drug Designation for treating congenital heart disease, specifically hypoplastic left heart syndrome (HLHS). This decision follows a successful randomized controlled trial demonstrating that Revascor significantly improves heart function in children with HLHS. The company confirmed its intention to meet with the FDA to discuss the approval pathway based on these results. Additionally, Mesoblast received Rare Pediatric Disease Designation for Revascor, highlighting its potential in pediatric cardiac care.
Read more →MESOThe results from the blinded, randomized, placebo-controlled prospective trial of REVASCOR conducted in the United States in children with HLHS were published in the December 2023 issue of the peer reviewed the Journal o
Mesoblast Limited has reported substantial progress in its clinical trials for its lead products, with promising results from a trial of REVASCOR in children with hypoplastic left heart syndrome (HLHS). The trial demonstrated significant improvements in heart function, leading to the FDA granting Rare Pediatric Disease Designation. The company is also preparing for further discussions with the FDA regarding approval pathways for REVASCOR and continues to advance its other Phase 3 programs for different conditions. Additionally, Mesoblast secured funding to bolster its operations and maintain momentum in ongoing clinical trials.
Read more →MESObeneficial to children with HLHS including neovascularization, anti-fibrosis, anti-apoptosis, immunomodulation, reduction in inflammation, and reversal of endothelial dysfunction. In the DREAM- HF randomized sham-placebo
Mesoblast Limited has been granted Rare Pediatric Disease Designation by the FDA for its cell therapy Revascor (rexlemestrocel-L) intended for use in children with hypoplastic left heart syndrome (HLHS). Clinical trial results indicate that the therapy significantly increases the size of the left heart chamber, which is crucial for successful surgical outcomes in these patients. Further, the company plans to meet with the FDA to discuss the prospect of expedited approval based on these promising results, given the urgent need for effective treatments in this life-threatening condition.
Read more →MESO▼ -6.2%on this news
appendix3g Notification of Issue, Conversion or Payment up of Unquoted Equity Securities Notification of Issue, Conversion or Payment up of Unquoted Equity Securities 1 / 7 Announcement Summary Entity name MESOBLAST LIMI
Mesoblast Limited has announced the issuance of 8,381,117 unquoted securities, specifically options set to expire on various dates and prices. This notification, dated January 15, 2024, includes details on securities distributed under an employee incentive scheme, which are not intended to be quoted on the ASX. Key management personnel were among those receiving a significant number of these securities, reflecting organizational commitment and strategy for future growth. The announcement suggests a continued evolution of Mesoblast's equity structure.
Read more →MESOadrratiochange {00876702} MESOBLAST MODIFIES RATIO FOR AMERICAN DEPOSITARY RECEIPT PROGRAM Mesoblast is consolidating the number of American Depositary Receipt ("ADR") on issue which trade on Nasdaq by implementing a rat
Mesoblast has announced a modification to its American Depositary Receipt (ADR) program, changing the ratio from 5 ordinary shares per ADR to 10 ordinary shares per ADR, resulting in a consolidation on a 1:2 basis. This change, effective January 10, 2024, will reduce the number of ADRs on issue while leaving the total number of ordinary shares unaffected. Mesoblast is known for its late-stage cellular therapies aimed at severe inflammatory conditions and continues to maintain a significant intellectual property portfolio.
Read more →MESOMesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
Mesoblast Limited has announced its filing for orphan drug designation and rare pediatric disease designation for its allogeneic cell therapy, rexlemestrocel-L, aimed at treating hypoplastic left heart syndrome (HLHS). The decision was based on positive outcomes from a clinical trial involving 19 children, indicating that the therapy may enhance left ventricular growth and function. These designations from the FDA could provide Mesoblast with various incentives, including tax credits and the potential for market exclusivity. Overall, this development positions Mesoblast favorably in the treatment of severe congenital heart disease.
Read more →MESOfda-hlhsannoun {00876702} MESOBLAST FILES FOR ORPHAN DRUG AND PEDIATRIC RARE DISEASE DESIGNATIONS FOR REXLEMESTROCEL-L AS TREATMENT FOR SEVERE CONGENITAL HEART DISEASE Melbourne, Australia; November 27 and New York, USA
Mesoblast Limited has filed for orphan drug designation and rare pediatric disease designation from the FDA for its cell therapy Rexlemestrocel-L, aimed at treating hypoplastic left heart syndrome (HLHS). The filings are based on encouraging results from a trial involving 19 children, showing significant improvement in left ventricular function. This therapy could potentially improve outcomes for children suffering from HLHS, an often fatal condition without intervention. The application for these designations could provide funding incentives and market exclusivity for Mesoblast if approved.
Read more →MESObmtctnannounce {00876702} MESOBLAST PARTNERS WITH BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK (BMT CTN) ON PIVOTAL TRIAL IN ADULTS WITH SR-aGVHD Melbourne, Australia; November 22 and New York, USA
Mesoblast Limited has announced a partnership with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a pivotal trial of its product Ryoncil in adults with steroid-refractory acute graft versus host disease (SR-aGVHD). This initiative is backed by support from the U.S. National Institutes of Health. The trial aims to evaluate the efficacy of Ryoncil in patients who are not responsive to existing therapies. Positive clinical data from pediatric trials enhances the potential of this new study to gain FDA approval.
Read more →MESOMesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
Mesoblast Limited has entered a partnership with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a pivotal Phase 3 trial of its lead product, Ryoncil (remestemcel-L), for adults suffering from steroid-refractory acute graft versus host disease (SR-aGVHD). This collaboration aims to address a significant unmet need as current treatments are lacking for this patient population. BMT CTN, which oversees a majority of US allogeneic transplants, will facilitate the development and execution of the trial. Mesoblast plans to submit the trial protocol to the FDA following independent reviews, furthering its mission to provide effective cellular medicines.
Read more →MESO▲ +6%on this news
appendix4c {00876702} APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023 Melbourne, Australia; October 31 and New York, USA
Mesoblast Limited has issued its Quarterly Activity Report for the quarter ending September 30, 2023, noting key meetings with the FDA regarding the approval pathways for Ryoncil in treating steroid-refractory acute graft versus host disease. The company reported high survival rates in pediatric cases treated with Ryoncil, showcasing improvements from clinical trials. Management has initiated cost containment measures expected to reduce operational expenses significantly while identifying additional revenue sources. The report highlighted a strong cash position with ongoing efforts to establish strategic partnerships and enhance financial stability.
Read more →MESO▲ +6%on this news
appendix4gandc Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 ME_214628133_1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity M
Mesoblast Limited has released its corporate governance statement for the financial year ending June 30, 2023. The statement, which adheres to ASX Listing Rules Appendix 4G, details the company's governance practices and compliance with ASX Corporate Governance Council recommendations. It has been approved as of October 12, 2023, and includes references to where disclosures can be found, ensuring transparency for stakeholders. The company has also provided links to its governance framework on its website.
Read more →MESOappendix3g Notification of Issue, Conversion or Payment up of Unquoted Equity Securities Notification of Issue, Conversion or Payment up of Unquoted Equity Securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMI
Mesoblast Limited has announced the issuance of 5,550,000 options expiring on various dates, under a scheme not quoted on ASX. This action is part of the company's ongoing strategy to incentivize employees. The options were issued on October 13, 2023, and are in addition to existing unquoted securities. The firm highlighted that these new options rank equally with existing securities in their class.
Read more →MESOmspooner3z Appendix 3Z Final Director's Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Rule 3.19A.3 Appendix 3Z Final Director's Interest Notice Information or documents not available no
The article presents a Final Director's Interest Notice for Mesoblast Limited, focusing on the disclosures related to director Michael Spooner. It highlights that Spooner has ceased to be a director as of September 26, 2023, and provides details of his interests in ordinary shares and options. The notice indicates a transition of some shares from direct to indirect holdings since the last communication. Additionally, there is a lack of available information regarding certain aspects of Spooner’s interests.
Read more →MESOregupdatextyp KEY OUTCOMES FROM FDA TYPE A MEETING AND MESOBLAST NEXT STEPS TO ACHIEVE RYONCIL APPROVAL Melbourne, Australia; September 21 and New York, USA
Mesoblast Limited provided an update on its lead product candidate, remestemcel-L, for treating pediatric and adult steroid-refractory acute graft versus host disease (SR-aGvHD) after a Type A meeting with the FDA. The FDA clarified that further evidence regarding the potency assay is needed for pediatric approval. Despite some regulatory hurdles, Mesoblast presented positive clinical data supporting the efficacy of RYONCIL, and intends to generate new potency data while planning a registration trial for adults. The company expects to receive formal minutes from the FDA regarding the meeting in about three weeks.
Read more →MESOannualreport MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL UPDATE FOR FISCAL YEAR ENDED JUNE 30, 2023 Melbourne, Australia; August 31 and New York, USA
Mesoblast Limited reported its fiscal year 2023 financial results, including a decrease in revenues and net operating cash usage. The company is focused on advancing its remestemcel-L therapy for pediatric SR-aGVHD, and a Type A meeting with the FDA is scheduled to discuss potential paths to approval. Cost containment measures are being implemented to manage cash reserves, with significant reductions in operational activity and salaries. The company remains committed to advancing its pivotal studies while adapting its strategies to meet regulatory requirements.
Read more →MESOMesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
Mesoblast Limited reported its financial results for the fiscal year ended June 30, 2023, highlighting ongoing progress in efforts to gain FDA approval for remestemcel-L to treat pediatric SR-aGVHD. The company has implemented cost containment measures, including payroll reductions, and is anticipating significant cash conservation moving forward. Despite a net loss of $81.9 million for the fiscal year and reduced revenues compared to the previous year, Mesoblast remains committed to advancing its clinical programs. A Type A meeting with the FDA is scheduled for mid-September to discuss the potential paths to approval.
Read more →MESO▼ -58.9%on this news· ran to -69% by day 3
About Steroid-Refractory Acute Graft Versus Host Disease Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT
Mesoblast Limited announced that the U.S. FDA has issued a complete response regarding its Biologics License Application for remestemcel-L, intended for pediatric steroid-refractory acute graft versus host disease. While the FDA's inspection found no safety concerns, the agency requires additional data for marketing approval, prompting the company to conduct a targeted study in high-risk adult patients. The BLA resubmission includes promising long-term survival data from previous trials, indicating the potential effectiveness of remestemcel-L in treating severe SR-aGVHD.
Read more →MESO▼ -58.9%on this news· ran to -69% by day 3
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Mesoblast Limited has received a complete response from the FDA regarding its BLA resubmission for remestemcel-L in pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). The FDA indicated that more data is needed to support the marketing approval, specifically requiring a targeted study in high-risk adults. While the company has achieved positive outcomes in pediatric trials, it must align with the FDA on the design of upcoming adult studies. Despite the setbacks, Mesoblast is determined to make remestemcel-L available to both children and adults suffering from SR-aGVHD.
Read more →MESO▲ +6.2%on this news· ran to +17% by day 3
This appendix is available as an online form Appendix 3G Notification of issue, conversion or payment up of unquoted equity +securities + See chapter 19 for defined terms 5 June 2021 Page 2 Part 2 - Type of issue Questio
Mesoblast Ltd has issued a notification regarding the issuance, conversion, or payment of unquoted equity securities. The announcement includes details about the forms and requirements for reporting these actions to the ASX. The document specifies that entities must provide necessary information and documentation to ensure compliance with regulatory standards. The latest update was communicated on July 7, 2023.
Read more →MESODocument Appendix 99.1 Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available.
Mesoblast Limited announced a Change of Director's Interest Notice regarding Philip R. Krause's holdings. As of June 5, 2023, he acquired 20,000 American Depositary Shares (ADSs), increasing his holdings to a total of 100,000 ordinary shares represented by these ADSs. The change was made through on-market trading on NASDAQ. No securities were disposed of during this transaction.
Read more →MESOMESOBLAST DIRECTOR PHILIP R. KRAUSE, M.D., APPOINTED TO STRATEGIC ADVISORY ROLE Melbourne, Australia June 5 and New York, USA
Mesoblast Limited has appointed Dr. Philip R. Krause to a strategic advisory role, enhancing its expertise in regulatory matters. Dr. Krause, a former deputy director at the FDA, will support Mesoblast's ongoing regulatory strategies for its remestemcel-L platform, aimed at treating severe inflammatory conditions. This role complements his current position as a board member and underscores Mesoblast's commitment to advancing its innovative therapies for serious diseases. The company continues to develop its cellular therapies while maintaining a robust intellectual property portfolio.
Read more →MESOMESOBLAST REPORTS OPERATIONAL AND FINANCIAL HIGHLIGHTS FOR QUARTER ENDED MARCH 31, 2023 Melbourne, Australia May 26 and New York, USA
Mesoblast Limited reports operational and financial highlights for Q1 2023, indicating progress for its therapies. The FDA has accepted the Biologics License Application (BLA) for remestemcel-L for steroid-refractory graft versus host disease, with an expected decision date of August 2, 2023. Additionally, the company received a Regenerative Medicine Advanced Therapy designation for rexlemestrocel-L, aimed at treating chronic low back pain. Financially, Mesoblast raised approximately $40 million through a private placement, ending the quarter with $48.8 million in cash.
Read more →MESO▲ +8%on this news
APPENDIX 4C QUARTERLY ACTIVITY REPORT Mesoblast Financial and Operational Highlights for Quarter Ended
Mesoblast Limited has reported its financial and operational highlights for the quarter ending March 31, 2023. The company raised approximately US$40 million through a global private placement and reported a cash balance of US$88.8 million post-funding. It has successfully resubmitted its Biologics License Application for remestemcel-L to the FDA, which has set a PDUFA goal date of August 2, 2023. Additionally, promising results from the DREAM-HF Phase 3 trial were published, demonstrating the efficacy of its mesenchymal precursor cell therapy.
Read more →MESO▼ -9.2%on this news
Mesoblast Completes Private Placement
Mesoblast Limited has completed a global private placement, raising around US$40 million to support its lead product, remestemcel-L. This funding is primarily from existing shareholders and aims to facilitate the treatment of children with steroid-refractory acute graft versus host disease, pending FDA approval. Additionally, the funds will bolster ongoing manufacturing efforts and the launch of a Phase 3 clinical trial for another product, rexlemestrocel-L. The company's strong intellectual property portfolio and established partnerships position it well in the market for allogeneic cellular medicines.
Read more →MESO▼ -9.2%on this newsshared move
MESOBLAST COMPLETES PRIVATE PLACEMENT New York, USA
Mesoblast Limited has successfully completed a global private placement, securing around US$40 million to support the launch of its lead cell therapy remestemcel-L for treating steroid-refractory acute graft versus host disease in children, pending FDA approval. Additionally, the company initiated plans for a Phase 3 clinical trial for rexlemestrocel-L, targeted at treating chronic low back pain. The upcoming FDA pre-licensure inspection of manufacturing capabilities in Singapore is also a crucial step forward for the company.
Read more →MESOFDA SCHEDULES PRE-LICENSE INSPECTION OF REMESTEMCEL-L MANUFACTURING Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date
The FDA has scheduled a pre-license inspection of Mesoblast's remestemcel-L manufacturing as part of the ongoing review of its Biologics License Application (BLA) for treating pediatric patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2023, for the application. If approved, remestemcel-L will be the first allogeneic cellular medicine available in the U.S. for children under 12 with this condition. The drug has shown promising clinical outcomes and has received Fast Track and Priority Review designations due to the serious nature of the disease and the need for effective treatments.
Read more →MESOThis appendix is available as an online form Only use this form if the online version is not available +Rule 3.10.3A, 3.10.3B, 3.10.3C, 3.10.3D Appendix 3G Notification of issue, conversion or payment up of unquoted equi
The article discusses the notification process for issuing unquoted equity securities by Mesoblast Ltd, specifically explaining the requirements for filing such notifications with the ASX. It mentions the company's obligations to provide information regarding unquoted and quoted securities, including the need for an International Securities Identification Number (ISIN) when applicable. Additionally, it outlines the necessary steps entities must follow when making these notifications.
Read more →MESO▼ -5.9%on this news· ran to +16% by day 1
FDA ACCEPTS MESOBLAST'S RESUBMISSION OF THE BIOLOGIC LICENSE APPLICATION FOR REMESTEMCEL-L IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE AS A COMPLETE RESPONSE AND SETS GOAL DATE OF AUGUST 2, 2023 I
Mesoblast Limited announced that the FDA has accepted its resubmission of the Biologics License Application (BLA) for remestemcel-L, targeting children with steroid-refractory acute graft vs host disease (SR-aGVHD). The FDA deemed the resubmission a complete response and set a goal date for review by August 2, 2023. This potential approval could provide the first allogeneic 'off-the-shelf' cellular medicine for the indicated demographic, addressing a significant unmet medical need, as current survival outcomes for severe SR-aGVHD have not improved over the past two decades.
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2022 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
Mesoblast Limited provided its half-year financial results for the period ending December 31, 2022. The report indicated a significant 39% decrease in revenues compared to the previous year, alongside a 15% increase in net losses attributed to members, totaling $41,370,000. The company also reported $30.7 million in cash outflows from operating activities, raising concerns about its ability to sustain operations without additional funding. Overall, the financial figures depict challenges for Mesoblast as it navigates its business strategy amidst these losses.
Read more →MESOMESOBLAST REPORTS OPERATIONAL AND FINANCIAL HIGHLIGHTS FOR QUARTER ENDED DECEMBER 31, 2022 Melbourne, Australia February 28 and New York, USA
Mesoblast Limited reported operational and financial highlights for the quarter ending December 31, 2022, emphasizing progress in their therapies for serious conditions. The Biologics License Application resubmission for remestemcel-L for treating steroid-refractory acute graft versus host disease is a key milestone, supported by positive long-term survival data. Additionally, the FDA granted RMAT designation for rexlemestrocel-L due to its potential in chronic lower back pain. The Phase 3 trial results for rexlemestrocel-L in chronic heart failure published in a leading cardiology journal further demonstrate the company's advancements in cellular medicines.
Read more →MESOREMESTEMCEL-L CLINICAL AND POTENCY STUDIES PRESENTED AT PREMIER MEETING OF TRANSPLANTATION RESEARCH AND THERAPY Melbourne, Australia February 17 and New York, USA
Mesoblast Limited announced the presentation of two studies on remestemcel-L, a treatment for steroid-refractory acute graft versus host disease (SR-aGVHD), at the 2023 Tandem Meetings. These studies, led by Dr. Joanne Kurtzberg, support the recent resubmission of the Biologics License Application (BLA) to the FDA. If approved, remestemcel-L would be the first allogeneic cellular medicine for children under 12 with this severe condition. The studies highlighted positive clinical outcomes, emphasizing the urgent need for effective therapies for SR-aGVHD in pediatric patients.
Read more →MESOFDA GRANTS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR REXLEMESTROCEL-L IN CHRONIC LOW BACK PAIN Melbourne, Australia February 9 and New York, USA
Mesoblast Limited announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its product rexlemestrocel-L, intended for the treatment of chronic low back pain associated with disc degeneration. This designation facilitates faster development and review processes due to the drug's potential to meet unresolved medical needs. Positive results from a Phase 3 trial demonstrated substantial pain relief and improved quality of life, especially in patients with less severe chronic low back pain. Mesoblast aims to collaborate with the FDA to gather further data for marketing approval.
Read more →MESO▲ +8.8%on this news· ran to +20% by day 3
APPENDIX 4C QUARTERLY ACTIVITY REPORT Mesoblast Operational and Financial Highlights for Quarter Ended
Mesoblast Limited, operational in cellular medicines, reported a 36% increase in revenue from royalties in its quarterly activity report for Q2 2022. Net cash usage for operating activities was reduced by 9% compared to the previous quarter, reflecting improved operational efficiency. The report also highlighted ongoing challenges in the commercial rollout of its products and the significant cash burn that the company continues to face as it advances its development programs.
Read more →MESOMesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Mesoblast Limited has resubmitted its Biologics License Application (BLA) to the FDA for remestemcel-L, aimed at treating steroid-refractory acute graft versus host disease (SR-aGVHD) in children. The resubmission includes new long-term survival data and further analyses confirming the treatment's effectiveness. If approved, remestemcel-L would be the first therapy available for children under 12 years old with this serious condition, addressing a significant unmet medical need. The FDA's review period could take up to six months after acceptance of the application.
Read more →MESOMESOBLAST AND OAKTREE EXTEND AVAILABILITY PERIOD OF UNDRAWN TRANCHES OF FINANCING FACILITY Melbourne, Australia; December 23 and New York, USA
MESOBLAST AND OAKTREE EXTEND AVAILABILITY PERIOD OF UNDRAWN TRANCHES OF FINANCING FACILITY Melbourne, Australia; December 23 and New York, USA; December 22, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases,
Read more →MESOMesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of remestemcel-L in the treatm
Read more →MESOCHILDREN TREATED WITH REMESTEMCEL-L SHOW LONG-TERM SURVIVAL THROUGH FOUR YEARS IN STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-aGVHD) Key Points: Long-term survival evident through 4 years in children treated w
CHILDREN TREATED WITH REMESTEMCEL-L SHOW LONG-TERM SURVIVAL THROUGH FOUR YEARS IN STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-aGVHD) Melbourne, Australia; November 23 and New York, USA; November 22, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allo
Read more →MESOCHANGE TO PROPOSED AMENDMENT TO THE CONSTITUTION REGARDING VIRTUAL MEETINGS Melbourne, Australia; November 15 and New York, USA
CHANGE TO PROPOSED AMENDMENT TO THE CONSTITUTION REGARDING VIRTUAL MEETINGS Melbourne, Australia; November 15 and New York, USA; November 14, 2022: Mesoblast Limited refers to its Notice of Annual General Meeting and Explanatory Memorandum dated 24 October 2022. In light of havi
Read more →MESORules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Mesoblast Limited ABN/ARBN Financial year ended: 109 431 870 30 June 2022 Our corporate gov
Rules 4.7.3 and 4.10.3 Corporate Governance Council Principles and Recommendations Name of entity Mesoblast Limited ABN/ARBN Financial year ended: 109 431 870 30 June 2022 Our corporate governance statement1 for the period above can be found at:2 These pages of our annual
Read more →MESOMesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022. Financial Highlights Net cash usage
Read more →MESONotification of cessation of +securities Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Friday
Announcement Summary Date of this announcement Friday October 14, 2022 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation MSBAI OPTION EXPIRING VARIOUS D
Read more →MESO▲ +7.3%on this news· ran to +17% by day 3
MESOBLAST SUBMITS NEW INFORMATION TO FDA IND FILE IN RESPONSE TO ITEMS IN THE CRL TO THE REMESTEMCEL-L BLA FOR SR-aGVHD Melbourne, Australia; October 3 and New York, USA
MESOBLAST SUBMITS NEW INFORMATION TO FDA IND FILE IN RESPONSE TO ITEMS IN THE CRL TO THE REMESTEMCEL-L BLA FOR SR-aGVHD Melbourne, Australia; October 3 and New York, USA; October 2, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines fo
Read more →MESO▼ -5.1%on this news
Appendix 99.1 Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Informati
Change of Director's Interest Notice Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/09/01 Amended 01/0
Read more →MESOAppendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Change of Director's Interest Notice Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/09/01 Amended 01/0
Read more →MESO▲ +8.4%on this news
MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR FISCAL YEAR ENDED JUNE 30, 2022 At
MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR FISCAL YEAR ENDED JUNE 30, 2022 Melbourne, Australia; August 31 and New York, USA; August 30, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseas
Read more →MESOMesoblast Corporate Update and Financial Results Webcast
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended J
Read more →MESOJANE BELL JOINS MESOBLAST BOARD Melbourne, Australia; August 18 and New York, USA
JANE BELL JOINS MESOBLAST BOARD Melbourne, Australia; August 18 and New York, USA; August 17, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of
Read more →MESO▼ -11.5%on this news
MESOBLAST COMPLETES US$45 MILLION PRIVATE PLACEMENT TO MAJOR SHAREHOLDERS Melbourne, Australia; August 9, and New York, USA
MESOBLAST COMPLETES US$45 MILLION PRIVATE PLACEMENT TO MAJOR SHAREHOLDERS Melbourne, Australia; August 9, and New York, USA; August 8, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has
Read more →MESOOnly use this form if the online version is not available +Rule 3.10.3E Appendix 3H Notification of cessation of +securities Information and documents given to ASX become ASX's property and may be made public. * Denotes
This appendix is available as an online formExhibit 99.1 Only use this form if the online version is not available+Rule 3.10.3E Notification of cessation of +securities Information and documents given to ASX become ASX's property and may be made public. *Denotes minimum infor
Read more →MESORelease authorized by the Chief Executive. For more information, please contact: Corporate Communications / Investors Media Paul Hughes Sumit Media T: +61 3 9639 6036 Grant Titmus E: investors@mesoblast.com T: +61 419 38
REXLEMESTROCEL-L TO BE HIGHLIGHTED AT MAXIM'S PANEL ON LATE-STAGE ADVANCEMENTS IN HEART FAILURE THERAPEUTICS AND MANAGEMENT Melbourne, Australia; July 12, and New York, USA; July 11, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines f
Read more →MESOregulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patie
Melbourne, Australia; June 14 and New York, USA; June 13, 2022 (ASX:MSB; Nasdaq:MESO): Further to our announcement of 19 May, 2022 regarding the proceeding served by the law firm William Roberts Lawyers, a second class action proceeding in the Federal Court of Australia canvassin
Read more →MESOMesoblast Key Opinion Leader Event Series for Investors & Analysts
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the current treatment landscape and unmet medical need for patients with chronic low back
Read more →MESOSURVIVAL OUTCOMES IN COVID-19 ARDS PATIENTS TREATED WITH REMESTEMCEL-L Melbourne, Australia; May 31 and New York, USA
SURVIVAL OUTCOMES IN COVID-19 ARDS PATIENTS TREATED WITH REMESTEMCEL-L Melbourne, Australia; May 31 and New York, USA; May 30, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on su
Read more →MESOthe potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's
Melbourne, Australia; May 19 and New York, USA; May 18, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that a class action proceeding in the Federal Court of Australia has been served on the Company by the law firm William Roberts Lawyers on behalf of persons who,
Read more →MESOAPPOINTMENT OF JOINT COMPANY SECRETARY Melbourne, Australia; April 6 and New York, USA
APPOINTMENT OF JOINT COMPANY SECRETARY Melbourne, Australia; April 6 and New York, USA; April 6, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Paul Hughes has been appointed as Joint
Read more →MESO▼ -6.9%on this news
PHILIP R. KRAUSE, M.D., FORMER FDA DEPUTY CHIEF FOR VACCINES, JOINS MESOBLAST BOARD Melbourne, Australia; March 24 and New York, USA
PHILIP R. KRAUSE, M.D., FORMER FDA DEPUTY CHIEF FOR VACCINES, JOINS MESOBLAST BOARD Melbourne, Australia; March 24 and New York, USA; March 23, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announc
Read more →MESOAppendix 3Z Final Director's Interest Notice Rule 3.19A.3 Appendix 3Z Final Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given
Final Director's Interest Notice Final Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/9/2001. Name of entity M
Read more →MESOConsolidated Income Statement Three Months Ended December 31, Six Months Ended December 31, (in U.S. dollars, in thousands, except per share amount) 2021 2020 2021 2020 Revenue 2,383 2,241 5,977 3,546 Research & developm
OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE PERIOD ENDED DECEMBER 31, 2021 Mesoblast Prepares for Resubmission of Biologics License Application Melbourne, Australia; February 25 and New York, USA; February 24, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global lead
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2021 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2021 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended June 30, 2021. H
Read more →MESORAPID IMPROVEMENT AND REMISSION IN PATIENTS WITH REFRACTORY ULCERATIVE COLITIS AND CROHN'S COLITIS AFTER DIRECT INJECTION OF REMESTEMCEL-L BY COLONOSCOPY Results of First Patient Cohort from Randomized Controlled Study P
RAPID IMPROVEMENT AND REMISSION IN PATIENTS WITH REFRACTORY ULCERATIVE COLITIS AND CROHN'S COLITIS AFTER DIRECT INJECTION OF REMESTEMCEL-L BY COLONOSCOPY Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn's and Colitis Organi
Read more →MESOMESOBLAST APPOINTS DR ERIC ROSE AS CHIEF MEDICAL OFFICER Melbourne, Australia; February 2, and New York, USA
MESOBLAST APPOINTS DR ERIC ROSE AS CHIEF MEDICAL OFFICER Melbourne, Australia; February 2, and New York, USA; February 1, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointm
Read more →MESOAPPENDIX 4C QUARTERLY ACTIVITY REPORT Mesoblast Prepares for Resubmission of Biologics License Application Melbourne, Australia; January 31 and New York, USA
APPENDIX 4C QUARTERLY ACTIVITY REPORT Mesoblast Prepares for Resubmission of Biologics License Application Melbourne, Australia; January 31 and New York, USA; January 30, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflamma
Read more →MESOMESOBLAST TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE "OPEN HOUSE" VIRTUAL CONFERENCE FROM JANUARY 25-27 TH , 2022 Melbourne, Australia; January 25, and New York, USA
MESOBLAST TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE "OPEN HOUSE" VIRTUAL CONFERENCE FROM JANUARY 25-27TH, 2022 Melbourne, Australia; January 25, and New York, USA; January 24, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines
Read more →MESO▼ -5.4%on this newsshared move
Only use this form if the online version is not available +Rule 3.10.3A, 3.10.3B, 3.10.3C, 3.10.3D Appendix 3G Notification of issue, conversion or payment up of unquoted equity +securities Note: this form is also used t
This appendix is available as an online form Exhibit 99.1 Only use this form if the online version is not available+Rule 3.10.3A, 3.10.3B, 3.10.3C, 3.10.3D Notification of issue, conversion or payment up of unquoted equity +securities Note: this form is also used to notify ASX
Read more →MESOSINGLE DOSE OF MESOBLAST'S ALLOGENEIC CELL THERAPY PROVIDES DURABLE PAIN REDUCTION FOR AT LEAST THREE YEARS IN PATIENTS WITH DEGENERATIVE DISC DISEASE 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented
SINGLE DOSE OF MESOBLAST'S ALLOGENEIC CELL THERAPY PROVIDES DURABLE PAIN REDUCTION FOR AT LEAST THREE YEARS IN PATIENTS WITH DEGENERATIVE DISC DISEASE 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase Melbourne, Australia; January 12,
Read more →MESOMESOBLAST PROVIDES UPDATE FOLLOWING MEETING WITH FDA'S OTAT ON REMESTEMCEL-L FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE Key Points: Meeting held with the US Food and Drug Administration's (FDA) Office of Tissues a
MESOBLAST PROVIDES UPDATE FOLLOWING MEETING WITH FDA'S OTAT ON REMESTEMCEL-L FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; December 31, and New York, USA; December 30, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular
Read more →MESO▲ +19.2%on this news
FDA'S OTAT IN AGREEMENT WITH 12-MONTH REDUCTION IN PAIN AS PRIMARY ENDPOINT FOR CHRONIC LOW BACK PAIN PROGRAM Melbourne, Australia; December 16, and New York, USA
FDA'S OTAT IN AGREEMENT WITH 12-MONTH REDUCTION IN PAIN AS PRIMARY ENDPOINT FOR CHRONIC LOW BACK PAIN PROGRAM Melbourne, Australia; December 16, and New York, USA; December 15, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inf
Read more →MESO▼ -6.5%on this news· ran to -32% by day 1shared move
UPDATE ON NOVARTIS AGREEMENT Melbourne, Australia; December 14, and New York, USA
UPDATE ON NOVARTIS AGREEMENT Melbourne, Australia; December 14, and New York, USA; December 13, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it has chosen to terminat
Read more →MESO▲ +12.7%on this news· ran to +25% by day 1
REXLEMESTROCEL-L SHOWS GREATEST TREATMENT BENEFIT ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN HIGH-RISK HEART FAILURE PATIENTS WITH DIABETES AND/OR MYOCARDIAL ISCHEMIA Endpoint in Line with FDA Guidance on Key Outcomes in
REXLEMESTROCEL-L SHOWS GREATEST TREATMENT BENEFIT ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN HIGH-RISK HEART FAILURE PATIENTS WITH DIABETES AND/OR MYOCARDIAL ISCHEMIA Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma Industry Drugs Approved
Read more →MESO▼ -5.2%on this newsshared move
CHAIRMAN'S ADDRESS TO SHAREHOLDERS 2021 MESOBLAST ANNUAL GENERAL MEETING 2021 has been a rollercoaster year for the world, and a challenging year of both meaningful progress as well as some setbacks for Mesoblast. We hav
CHAIRMAN'S ADDRESS TO SHAREHOLDERS 2021 MESOBLAST ANNUAL GENERAL MEETING 2021 has been a rollercoaster year for the world, and a challenging year of both meaningful progress as well as some setbacks for Mesoblast. We have gone from the elation of seeing a United States Food and
Read more →MESOMESOBLAST AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILITY Melbourne, Australia; November 22, and New York, USA
MESOBLAST AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILITY Melbourne, Australia; November 22, and New York, USA; November 21, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases,
Read more →MESO▲ +13.1%on this news
LATE BREAKING PRESENTATION AT AMERICAN HEART ASSOCIATION ANNUAL MEETING OF LANDMARK PHASE 3 TRIAL OF REXLEMESTROCEL-L IN CHRONIC HEART FAILURE Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attack
LATE BREAKING PRESENTATION AT AMERICAN HEART ASSOCIATION ANNUAL MEETING OF LANDMARK PHASE 3 TRIAL OF REXLEMESTROCEL-L IN CHRONIC HEART FAILURE Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Infl
Read more →MESORules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Mesoblast Limited ABN/ARBN Financial year ended: 109 431 870 30 June 2021 Our corporate gov
Rules 4.7.3 and 4.10.3 Corporate Governance Council Principles and Recommendations ABN/ARBN Financial year ended: 109 431 870 30 June 2021 Our corporate governance statement1 for the period above can be found at:2 These pages of our annual report: This URL on our website
Read more →MESOAPPENDIX 4C QUARTERLY ACTIVITY REPORT Financial and Operational Highlights for Quarter Ended
APPENDIX 4C QUARTERLY ACTIVITY REPORT Financial and Operational Highlights for Quarter Ended September 30, 2021 Melbourne, Australia; October 29 and New York, USA; October 28, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inf
Read more →MESO▲ +7.2%on this news
This appendix is available as an online form Appendix 99.1 Only use this form if the online version is not available +Rule 3.10.3A, 3.10.3B, 3.10.3C, 3.10.3D Appendix 3G Notification of issue, conversion or payment up of
This appendix is available as an online form Appendix 99.1 Only use this form if the online version is not available+Rule 3.10.3A, 3.10.3B, 3.10.3C, 3.10.3D Notification of issue, conversion or payment up of unquoted equity +securities Note: this form is also used to notify AS
Read more →MESOREXLEMESTROCEL-L PHASE 3 TRIAL RESULTS IN CHRONIC HEART FAILURE SELECTED AS LATE BREAKING PRESENTATION AT AMERICAN HEART ASSOCIATION ANNUAL MEETING Melbourne, Australia; October 7, and New York, USA
REXLEMESTROCEL-L PHASE 3 TRIAL RESULTS IN CHRONIC HEART FAILURE SELECTED AS LATE BREAKING PRESENTATION AT AMERICAN HEART ASSOCIATION ANNUAL MEETING Melbourne, Australia; October 7, and New York, USA; October 6, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in all
Read more →MESO▼ -7.4%on this news
Consolidated Income Statement Year Ended June 30, (in U.S. dollars, in thousands, except per share amount) 2021 2020 Revenue 7,456 32,156 Research & development (53,012 ) (56,188 ) Manufacturing commercialization (32,719
OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE YEAR Melbourne, Australia; August 31 and New York, USA; August 30, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights
Read more →MESOMANAGEMENT CHANGES POST-FINANCIAL YEAR END Melbourne, Australia; August 10, and New York, USA
MANAGEMENT CHANGES POST-FINANCIAL YEAR END Melbourne, Australia; August 10, and New York, USA; August 9, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that effective August 30, 2021, post
Read more →MESOMESOBLAST PRESENTS RESPIRATORY FUNCTION RESULTS OF COVID-19 ARDS TRIAL AT PULMONARY DISEASE CONFERENCE Melbourne, Australia; July 16 and New York, USA
MESOBLAST PRESENTS RESPIRATORY FUNCTION RESULTS OF COVID-19 ARDS TRIAL AT PULMONARY DISEASE CONFERENCE Melbourne, Australia; July 16 and New York, USA; July 15, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseas
Read more →MESOMESOBLAST PROVIDES UPDATE ON PROGRAM FOR CHRONIC LOW BACK PAIN DUE TO DEGENERATIVE DISC DISEASE Melbourne, Australia; July 1, and New York, USA
MESOBLAST PROVIDES UPDATE ON PROGRAM FOR CHRONIC LOW BACK PAIN DUE TO DEGENERATIVE DISC DISEASE Melbourne, Australia; July 1, and New York, USA; June 30, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, tod
Read more →MESOConsolidated Income Statement Three Months Ended March 31, Nine Months Ended March 31, (in U.S. dollars, in thousands, except per share amount) 2021 2020 2021 2020 Revenue 1,915 12,201 5,461 31,455 Research & development
OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 2021 Melbourne, Australia; June 3 and New York, USA; June 2, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported opera
Read more →MESOIMPROVED OUTCOMES IN INFLAMMATORY LUNG DISEASE WITH REMESTEMCEL-L PUBLISHED IN RESPIRATORY RESEARCH JOURNAL Melbourne, Australia; May 25 and New York, USA
IMPROVED OUTCOMES IN INFLAMMATORY LUNG DISEASE WITH REMESTEMCEL-L PUBLISHED IN RESPIRATORY RESEARCH JOURNAL Melbourne, Australia; May 25 and New York, USA; May 24, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory dis
Read more →MESOREMESTEMCEL-L REDUCES MORTALITY IN PATIENTS LESS THAN 65 YEARS OLD WITH MODERATE/SEVERE COVID-19 ARDS: TOPLINE 60-DAY RESULTS FROM RANDOMIZED CONTROLLED TRIAL Remestemcel-L reduced mortality through 60 days in the pre-sp
REMESTEMCEL-L REDUCES MORTALITY IN PATIENTS LESS THAN 65 YEARS OLD WITH MODERATE/SEVERE COVID-19 ARDS: TOPLINE 60-DAY RESULTS FROM RANDOMIZED CONTROLLED TRIAL Melbourne, Australia; April 30 and New York, USA; April 29, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leade
Read more →MESOMesoblast Corporate Update
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update. The webcast will begin at 9.00am AEST, Friday, April 30; 7.00
Read more →MESOInitial Director's Interest Notice Rule 3.19A.1 Appendix 3X Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX
Appendix 3X Exhibit 99.1 Initial Director's Interest Notice Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced
Read more →MESOMESOBLAST OPERATIONAL HIGHLIGHTS AND UPCOMING MILESTONES Melbourne, Australia; March 31 and New York, USA
MESOBLAST OPERATIONAL HIGHLIGHTS AND UPCOMING MILESTONES Melbourne, Australia; March 31 and New York, USA; March 30, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Compan
Read more →MESOPHILIP J. FACCHINA, CHIEF STRATEGY OFFICER AND PRINCIPAL OF SURGCENTER DEVELOPMENT, JOINS MESOBLAST BOARD Melbourne, Australia; March 29 and New York, USA
PHILIP J. FACCHINA, CHIEF STRATEGY OFFICER AND PRINCIPAL OF SURGCENTER DEVELOPMENT, JOINS MESOBLAST BOARD Melbourne, Australia; March 29 and New York, USA; March 28, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory d
Read more →MESOMESOBLAST CLOSES US$110/A$138 MILLION FINANCING LED BY US STRATEGIC INVESTOR GROUP Melbourne, Australia; March 9 and New York, USA
MESOBLAST CLOSES US$110/A$138 MILLION FINANCING LED BY US STRATEGIC INVESTOR GROUP Melbourne, Australia; March 9 and New York, USA; March 8, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, announced today
Read more →MESOPlease fill in and submit as a PDF announcement +Rule 2.7 Appendix 2A Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documen
This appendix is not available as an online formExhibit 99.1 Please fill in and submit as a PDF announcement+Rule 2.7 Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2020 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2020 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended June 30, 2020. H
Read more →MESOMESOBLAST COMPLETES US$110/A$138 MILLION FINANCING LED BY US STRATEGIC INVESTOR GROUP Melbourne, Australia; March 2 and New York, USA
MESOBLAST COMPLETES US$110/A$138 MILLION FINANCING LED BY US STRATEGIC INVESTOR GROUP Melbourne, Australia; March 2 and New York, USA; March 1, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) announced today it has entered into subscription agreements for a total of US$110 millio
Read more →MESOPOSITIVE OUTCOMES OF FIRST CHILDREN TREATED WITH REMESTEMCEL-L FOR MULTISYSTEM INFLAMMATORY SYNDROME (MIS-C) AND HEART FAILURE POST-COVID-19 PUBLISHED IN PEDIATRICS Melbourne, Australia; February 17, and New York, USA
POSITIVE OUTCOMES OF FIRST CHILDREN TREATED WITH REMESTEMCEL-L FOR MULTISYSTEM INFLAMMATORY SYNDROME (MIS-C) AND HEART FAILURE POST-COVID-19 PUBLISHED IN PEDIATRICS Melbourne, Australia; February 17, and New York, USA; February 16, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO),
Read more →MESOMESOBLAST PHASE 3 TRIAL SHOWS THAT A SINGLE INJECTION OF REXLEMESTROCEL-L + HYALURONIC ACID CARRIER RESULTS IN AT LEAST TWO YEARS OF PAIN REDUCTION WITH OPIOID SPARING ACTIVITY IN PATIENTS WITH CHRONIC LOW BACK PAIN DUE
MESOBLAST PHASE 3 TRIAL SHOWS THAT A SINGLE INJECTION OF REXLEMESTROCEL-L + HYALURONIC ACID CARRIER RESULTS IN AT LEAST TWO YEARS OF PAIN REDUCTION WITH OPIOID SPARING ACTIVITY IN PATIENTS WITH CHRONIC LOW BACK PAIN DUE TO DEGENERATIVE DISC DISEASE Melbourne, Australia; February
Read more →MESOMesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the second quarter
Read more →MESOMesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF
Read more →MESOSINGLE DOSE OF REXLEMESTROCEL-L PROVIDES SUBSTANTIAL AND DURABLE REDUCTION IN HEART ATTACKS, STROKES AND CARDIAC DEATH IN PATIENTS WITH CHRONIC HEART FAILURE Melbourne, Australia; January 11, and New York, USA
SINGLE DOSE OF REXLEMESTROCEL-L PROVIDES SUBSTANTIAL AND DURABLE REDUCTION IN HEART ATTACKS, STROKES AND CARDIAC DEATH IN PATIENTS WITH CHRONIC HEART FAILURE Melbourne, Australia; January 11, and New York, USA; January 10, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global l
Read more →MESOMesoblast Webcast – Update on COVID-19 ARDS Trial
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an update on the randomized controlled trial of remestemcel-L in ventilator-depende
Read more →MESOMESOBLAST UPDATE ON COVID-19 ARDS TRIAL Melbourne, Australia; December 18, and New York, USA
MESOBLAST UPDATE ON COVID-19 ARDS TRIAL Melbourne, Australia; December 18, and New York, USA; December 17, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate t
Read more →MESOMesoblast Update on COVID-19 ARDS Trial
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 in
Read more →MESOMESOBLAST PROVIDES TOPLINE RESULTS FROM PHASE 3 TRIAL OF REXLEMESTROCEL-L FOR ADVANCED CHRONIC HEART FAILURE Melbourne, Australia; December 15, and New York, USA
MESOBLAST PROVIDES TOPLINE RESULTS FROM PHASE 3 TRIAL OF REXLEMESTROCEL-L FOR ADVANCED CHRONIC HEART FAILURE Melbourne, Australia; December 15, and New York, USA; December 14, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for infl
Read more →MESOMesoblast Limited Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before December 7, 2020; click here to submit trade information LOS ANGELES, Dec. 04, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Mesoblast Limit
Read more →MESOFDA GRANTS FAST TRACK DESIGNATION FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 Melbourne, Australia; December 2 and New York; USA
FDA GRANTS FAST TRACK DESIGNATION FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 Melbourne, Australia; December 2 and New York; USA; December 1, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medici
Read more →MESOCHAIRMAN'S ADDRESS TO SHAREHOLDERS 2020 MESOBLAST ANNUAL GENERAL MEETING This has been an unprecedented year due to the coronavirus pandemic, its impact on human health, and the associated collateral economic damage worl
CHAIRMAN'S ADDRESS TO SHAREHOLDERS 2020 MESOBLAST ANNUAL GENERAL MEETING This has been an unprecedented year due to the coronavirus pandemic, its impact on human health, and the associated collateral economic damage worldwide. The Mesoblast team has responded with great agility
Read more →MESOMesoblast Limited Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
Investors with losses are encouraged to contact the firm before December 7, 2020; click here to submit trade information LOS ANGELES, Nov. 18, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Mesoblast Limite
Read more →MESOMESOBLAST ENTERS GLOBAL COLLABORATION FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF REMESTEMCEL-L Initial Focus on Acute Respiratory Distress Syndrome, including COVID-19 Melbourne, Australia; November 20, and Ne
MESOBLAST ENTERS GLOBAL COLLABORATION FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF REMESTEMCEL-L Initial Focus on Acute Respiratory Distress Syndrome, including COVID-19 Melbourne, Australia; November 20, and New York, USA; November 19, 2020: Mesoblast Limited (ASX:MSB
Read more →MESOSECOND INTERIM ANALYSIS OF CLINICAL OUTCOMES AFTER 135 PATIENTS RESULTS IN RECOMMENDATION TO CONTINUE REMESTEMCEL-L PHASE 3 TRIAL IN COVID-19 ARDS Melbourne, Australia; November 11, and New York, USA
SECOND INTERIM ANALYSIS OF CLINICAL OUTCOMES AFTER 135 PATIENTS RESULTS IN RECOMMENDATION TO CONTINUE REMESTEMCEL-L PHASE 3 TRIAL IN COVID-19 ARDS Melbourne, Australia; November 11, and New York, USA; November 10, 2020: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced
Read more →MESOKey to Disclosures Corporate Governance Council Principles and Recommendations Rules 4.7.3 and 4.10.3 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Introduced 01/07/14 Amend
Appendix 4G Exhibit 99.1 Key to Disclosures Corporate Governance Council Principles and Recommendations Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations Introduced 01/07/14 Amended 02/11/15 Name of entity Mesoblast Limited ABN / ARBN Financ
Read more →MESOUPDATE ON REMESTEMCEL-L FOR THE TREATMENT OF COVID-19 ARDS AND STEROID-REFRACTORY ACUTE GVHD Quarterly Activity Report Melbourne, Australia, October 29, and New York; USA
UPDATE ON REMESTEMCEL-L FOR THE TREATMENT OF COVID-19 ARDS AND STEROID-REFRACTORY ACUTE GVHD Quarterly Activity Report Melbourne, Australia, October 29, and New York; USA; October 28, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines
Read more →MESORANDOMIZED CONTROLLED STUDY USING DIRECT INJECTION OF REMESTEMCEL-L INTO INFLAMED GUT OF PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS Melbourne, Australia
RANDOMIZED CONTROLLED STUDY USING DIRECT INJECTION OF REMESTEMCEL-L INTO INFLAMED GUT OF PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS Melbourne, Australia; October 22, 2020 and New York, USA; October 21, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in al
Read more →MESORANDOMIZED CONTROLLED PHASE 3 TRIAL OF REMESTEMCEL-L FOR REDUCED MORTALITY IN COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME SURPASSES 50% ENROLLMENT Melbourne, Australia; October 13 and New York, USA
RANDOMIZED CONTROLLED PHASE 3 TRIAL OF REMESTEMCEL-L FOR REDUCED MORTALITY IN COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME SURPASSES 50% ENROLLMENT Melbourne, Australia; October 13 and New York, USA; October 12, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in al
Read more →MESOMESOBLAST ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Mesoblast Limited and Encourages Investors to Contact the Firm
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that
Read more →MESOMESOBLAST RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR BIOLOGICS LICENSE APPLICATION FOR STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE IN CHILDREN Melbourne, Australia
MESOBLAST RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR BIOLOGICS LICENSE APPLICATION FOR STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE IN CHILDREN Melbourne, Australia; October 2, 2020 and New York, USA; October 1, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), globa
Read more →MESOMESOBLAST WINS 2020 FIERCE BIOTECH INNOVATION OF THE YEAR AWARD FOR REMESTEMCEL-L Melbourne, Australia; September 15 and New York; USA
MESOBLAST WINS 2020 FIERCE BIOTECH INNOVATION OF THE YEAR AWARD FOR REMESTEMCEL-L Melbourne, Australia; September 15 and New York; USA; September 14, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today a
Read more →MESODATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF REMESTEMCEL-L PHASE 3 TRIAL IN COVID-19 PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME Melbourne, Australia
DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF REMESTEMCEL-L PHASE 3 TRIAL IN COVID-19 PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME Melbourne, Australia; September 4, 2020 and New York, USA; September 3, 2020: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announ
Read more →MESOMESOBLAST RECEIVES ETHICS APPROVAL TO TREAT COVID-19 PATIENTS IN AUSTRALIA Melbourne, Australia
MESOBLAST RECEIVES ETHICS APPROVAL TO TREAT COVID-19 PATIENTS IN AUSTRALIA Melbourne, Australia; September 2, 2020 and New York; USA; September 1, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today anno
Read more →MESOMESOBLAST REPORTS SUBSTANTIAL OPERATIONAL PROGRESS AND FINANCIAL RESULTS FOR THE YEAR ENDED JUNE 30, 2020 Mesoblast Well Prepared Ahead of First Potential US Product Launch Melbourne, Australia
MESOBLAST REPORTS SUBSTANTIAL OPERATIONAL PROGRESS AND FINANCIAL RESULTS FOR THE YEAR ENDED JUNE 30, 2020 Mesoblast Well Prepared Ahead of First Potential US Product Launch Melbourne, Australia, August 27, 2020 and New York, USA, August 26, 2020: Mesoblast Limited (ASX:MSB; Nas
Read more →MESOMesoblast 2020 Full Year Financial Results Webcast
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss its financial and operational highlights for the fourth quarter and full-year ended June 30, 2020 (F
Read more →MESOMesoblast Limited Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, Aug. 19, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mesoblast Limited ("Mesoblast" or the "Company") (Nasdaq: MESO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. T
Read more →MESOU.S. FDA ADVISORY COMMITTEE VOTES NINE TO ONE IN FAVOR OF REMESTEMCEL-L (RYONCIL ) FOR EFFICACY IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia
U.S. FDA ADVISORY COMMITTEE VOTES NINE TO ONE IN FAVOR OF REMESTEMCEL-L (RYONCIL ) FOR EFFICACY IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; August 14, 2020; and New York, USA; August 13, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO
Read more →MESOUPDATE ON SCHEDULED FDA ADVISORY COMMITTEE MEETING Melbourne, Australia
UPDATE ON SCHEDULED FDA ADVISORY COMMITTEE MEETING Melbourne, Australia; August 11, 2020; and New York, USA; August 10, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today provided an update on the scheduled meeting of the Oncologic Drugs Advisory Committee (ODAC) of the United
Read more →MESOMESOBLAST PROVIDES REMESTEMCEL-L UPDATE AND QUARTERLY ACTIVITY REPORT Melbourne, Australia
MESOBLAST PROVIDES REMESTEMCEL-L UPDATE AND QUARTERLY ACTIVITY REPORT Melbourne, Australia, July 30, 2020, and New York; USA; July 29, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an upda
Read more →MESOFDA ADVISORY COMMITTEE SETS REVIEW DATE FOR MESOBLAST'S REMESTEMCEL-L IN PEDIATRIC STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia
FDA ADVISORY COMMITTEE SETS REVIEW DATE FOR MESOBLAST'S REMESTEMCEL-L IN PEDIATRIC STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; July 21, 2020; and New York, USA; July 20, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the Oncologi
Read more →MESOJuly 2020 Issue to Kentgrove Capital In connection with the Kentgrove Capital equity facility agreement entered into in 2016, and the extension of the term of the facility which occurred in 2019, Mesoblast needs to issue
In connection with the Kentgrove Capital equity facility agreement entered into in 2016, and the extension of the term of the facility which occurred in 2019, Mesoblast needs to issue 1,500,000 new incentive rights and 74,924 ordinary shares to Kentgrove Capital. A prospectus ha
Read more →MESOEXPANDED ACCESS PROTOCOL INITIATED FOR COMPASSIONATE USE OF REMESTEMCEL-L IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH COVID-19 Melbourne, Australia
EXPANDED ACCESS PROTOCOL INITIATED FOR COMPASSIONATE USE OF REMESTEMCEL-L IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH COVID-19 Melbourne, Australia; July 6, 2020; and New York, USA; July 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced tha
Read more →MESOPlease fill in and submit as a PDF announcement +Rule 3.10.3A, 3.10.3B, 3.10.3C Appendix 3G Notification of issue, conversion or payment up of equity +securities Information or documents not available now must be given t
This appendix is not available as an online formExhibit 99.1 Please fill in and submit as a PDF announcement+Rule 3.10.3A, 3.10.3B, 3.10.3C Notification of issue, conversion or payment up of equity +securities Information or documents not available now must be given to ASX as
Read more →MESOREMESTEMCEL-L IMPROVES RESPIRATORY AND FUNCTIONAL OUTCOMES IN PATIENTS WITH INFLAMMATORY LUNG DISEASE Phase 2 Trial Results Presented At 2020 International Society for Cell & Gene Therapy Annual Meeting Melbourne, Austra
REMESTEMCEL-L IMPROVES RESPIRATORY AND FUNCTIONAL OUTCOMES IN PATIENTS WITH INFLAMMATORY LUNG DISEASE Phase 2 Trial Results Presented At 2020 International Society for Cell & Gene Therapy Annual Meeting Melbourne, Australia; June 1, 2020 and New York, USA; May 31, 2020: Mesobla
Read more →MESOMESOBLAST REPORTS STRONG FINANCIAL POSITION AND SUBSTANTIAL OPERATIONAL PROGRESS FOR THE PERIOD ENDED MARCH 31, 2020 Melbourne, Australia
MESOBLAST REPORTS STRONG FINANCIAL POSITION AND SUBSTANTIAL OPERATIONAL PROGRESS FOR THE PERIOD ENDED MARCH 31, 2020 Melbourne, Australia, May 28, 2020 and New York, USA, May 27, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for i
Read more →MESOMesoblast to Host Analyst Call on Financial Results for Period Ended March 31, 2020
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the period ended March 31, 2020. The webcast will begin at 6pm EDT We
Read more →MESOCLINICAL OUTCOMES USING RYONCIL (REMESTEMCEL-L) IN CHILDREN AND ADULTS WITH SEVERE INFLAMMATORY GRAFT VERSUS HOST DISEASE PUBLISHED IN THREE ARTICLES IN BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Key points: • Bi
CLINICAL OUTCOMES USING RYONCIL (REMESTEMCEL-L) IN CHILDREN AND ADULTS WITH SEVERE INFLAMMATORY GRAFT VERSUS HOST DISEASE PUBLISHED IN THREE ARTICLES IN BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Melbourne, Australia; May 25, 2020; and New York, USA; May 24, 2020: Mesoblast Lim
Read more →MESOMESOBLAST SUCCESSFULLY COMPLETES FINANCING TO SCALE-UP MANUFACTURING OF REMESTEMCEL-L FOR COVID-19 ARDS Melbourne, Australia
MESOBLAST SUCCESSFULLY COMPLETES FINANCING TO SCALE-UP MANUFACTURING OF REMESTEMCEL-L FOR COVID-19 ARDS Melbourne, Australia; May 13, 2020; and New York, USA, May 12, 2020: Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a leader in cellular medicines for inflammatory diseases, anno
Read more →MESOFIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST ' S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME Melbourne, Australia
FIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST'S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME Melbourne, Australia; May 6, 2020; and New York, USA; May 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular med
Read more →MESOPHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L IN 300 PATIENTS WITH COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME BEGINS ENROLLMENT Melbourne, Australia
PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L IN 300 PATIENTS WITH COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME BEGINS ENROLLMENT Melbourne, Australia; April 30, 2020; and New York, USA; April 29, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular
Read more →MESOSURVIVAL IN COVID-19 PATIENTS WITH MODERATE/SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME TREATED IN NEW YORK WITH MESOBLAST'S CELL THERAPY REMESTEMCEL-L Key points: 83% survival in ventilator-dependent COVID-19 patients (1
83% SURVIVAL IN COVID-19 PATIENTS WITH MODERATE/SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME TREATED IN NEW YORK WITH MESOBLAST'S CELL THERAPY REMESTEMCEL-L 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARD
Read more →MESOMESOBLAST TO PRESENT POSITIVE CLINICAL OUTCOMES USING REMESTEMCEL-L IN PATIENTS WITH INFLAMMATORY LUNG DISEASE AT 2020 INTERNATIONAL SOCIETY OF CELL AND GENE THERAPY ANNUAL MEETING Melbourne, Australia; Friday
MESOBLAST TO PRESENT POSITIVE CLINICAL OUTCOMES USING REMESTEMCEL-L IN PATIENTS WITH INFLAMMATORY LUNG DISEASE AT 2020 INTERNATIONAL SOCIETY OF CELL AND GENE THERAPY ANNUAL MEETING Melbourne, Australia; Friday April 17, 2020 and New York, USA; April 16, 2020: Mesoblast Limited (
Read more →MESOMESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH'S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L
MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH'S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO
Read more →MESOFDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE respiratory DISTRESS SYNDROME CAUSED BY COVID-19 Melbourne, Australia
FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE respiratory DISTRESS SYNDROME CAUSED BY COVID-19 Melbourne, Australia; April 6, 2020; and New York, USA; April 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global lea
Read more →MESOCLINICAL OUTCOMES OF MESOBLAST'S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS Melbourne, Australia
CLINICAL OUTCOMES OF MESOBLAST'S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS Melbourne, Australia; March 30, 2020; and New York, USA; March 29, 2020: Results from a sub-study of 70 patients with end-sta
Read more →MESOThis appendix is not available as an online form Please fill in and submit as a PDF announcement +Rule 2.7 Appendix 2A Application for quotation of +securities Information or documents not available now must be given to
This appendix is not available as an online form Please fill in and submit as a PDF announcement+Rule 2.7 Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becom
Read more →MESOMESOBLAST TO EVALUATE ANTI-INFLAMMATORY CELL THERAPY REMESTEMCEL-L FOR TREATMENT OF COVID-19 LUNG DISEASE Melbourne, Australia
MESOBLAST TO EVALUATE ANTI-INFLAMMATORY CELL THERAPY REMESTEMCEL-L FOR TREATMENT OF COVID-19 LUNG DISEASE Melbourne, Australia; March 10, 2020; and New York, USA; March 9, 2020: Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that it plans to evaluate its allogeneic me
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2019 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2019 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended June 30, 2019. H
Read more →MESOMesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019
NEW YORK and MELBOURNE, Australia, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported financial, corporate and operational highlights for the half year ended December 31, 2019. Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very
Read more →MESOMesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019
NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the first half FY 2020 ended December 31, 2019. The webcast will beg
Read more →MESOCLINICALLY MEANINGFUL OUTCOMES USING REMESTEMCEL-L IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE Melbourne, Australia
CLINICALLY MEANINGFUL OUTCOMES USING REMESTEMCEL-L IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE Melbourne, Australia, February 20, 2020 and New York, USA, February 19, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory dis
Read more →MESOMESOBLAST SUBMITS COMPLETED BIOLOGICS LICENSE APPLICATION FOR RYONCIL TO US FDA Melbourne, Australia
MESOBLAST SUBMITS COMPLETED BIOLOGICS LICENSE APPLICATION FOR RYONCIL TO US FDA Melbourne, Australia; February 3, 2020; and New York, USA; February 2, 2020 Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced t
Read more →MESOMESOBLAST QUARTERLY CASH FLOW REPORT Continued Revenue Growth in Japan Provides Framework for First Product Commercialization in United States Melbourne, Australia
MESOBLAST QUARTERLY CASH FLOW REPORT Continued Revenue Growth in Japan Provides Framework for First Product Commercialization in United States Melbourne, Australia, January 29, 2020 and New York, USA, January 28, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in
Read more →MESOMESOBLAST PRESENTS COMMERCIAL PLANS AT 2020 BIOTECH SHOWCASE IN SAN FRANCISCO Announces Ryoncil as Brand Name for First Planned US Product Launch Melbourne, Australia; January 15 and New York, USA
MESOBLAST PRESENTS COMMERCIAL PLANS AT 2020 BIOTECH SHOWCASE IN SAN FRANCISCO Announces Ryoncil as Brand Name for First Planned US Product Launch Melbourne, Australia; January 15 and New York, USA; January 14, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in all
Read more →MESOMESOBLAST SUBMITS CLINICAL EFFICACY AND SAFETY DATA TO FDA IN ROLLING BIOLOGICS LICENSE APPLICATION FOR REMESTEMCEL-L Melbourne, Australia
MESOBLAST SUBMITS CLINICAL EFFICACY AND SAFETY DATA TO FDA IN ROLLING BIOLOGICS LICENSE APPLICATION FOR REMESTEMCEL-L Melbourne, Australia; January 2, 2020; and New York, USA; January 1, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inf
Read more →MESOMESOBLAST'S PHASE 3 TRIAL OF REVASCOR IN ADVANCED CHRONIC HEART FAILURE SURPASSES THE NUMBER OF PRIMARY ENDPOINT EVENTS FOR TRIAL COMPLETION Melbourne, Australia
MESOBLAST'S PHASE 3 TRIAL OF REVASCOR IN ADVANCED CHRONIC HEART FAILURE SURPASSES THE NUMBER OF PRIMARY ENDPOINT EVENTS FOR TRIAL COMPLETION Melbourne, Australia; December 17, 2019 and New York, USA; December 16, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced t
Read more →MESOINTERVIEW WITH MESOBLAST CHAIRMAN JOSEPH R. SWEDISH 2019
INTERVIEW WITH MESOBLAST CHAIRMAN JOSEPH R. SWEDISH 2019 MESOBLAST ANNUAL GENERAL MEETING Joseph R. Swedish was Executive Chairman, President and CEO of Anthem Inc., a Fortune 33 company and the leading health benefits provider in the United States. For 12 consecutive years, Mo
Read more →MESOMESOBLAST FINANICAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2019 Continued Increase in Revenues and Strong Balance Sheet Melbourne, Australia
MESOBLAST FINANICAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2019 Continued Increase in Revenues and Strong Balance Sheet Melbourne, Australia, November 26, 2019 and New York, USA, November 25, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported operational highlig
Read more →MESOMesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019
NEW YORK and MELBOURNE, Australia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the quarter ended September 30, 2019. The w
Read more →MESOMESOBLAST QUARTERLY CASH FLOW REPORT Strong Balance Sheet for First Product Commercialization In United States Following Strategic Partnership In Europe and Capital Raise Melbourne, Australia
MESOBLAST QUARTERLY CASH FLOW REPORT Strong Balance Sheet for First Product Commercialization In United States Following Strategic Partnership In Europe and Capital Raise Melbourne, Australia, October 31, 2019 and New York, USA, October 30, 2019: Mesoblast Limited (ASX:MSB; Nas
Read more →MESOAPPOINTMENT OF JOINT COMPANY SECRETARY New York, USA; and Melbourne, Australia
APPOINTMENT OF JOINT COMPANY SECRETARY New York, USA; and Melbourne, Australia; October 29, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Niva Sivakumar has been appointed as Joint Company Secretary of Mesoblast Limited, together with Charlie Harrison. Mr
Read more →MESOMESOBLAST AND LONZA ENTER INTO AGREEMENT FOR COMMERCIAL MANUFACTURE OF MESOBLAST'S POTENTIAL FIRST UNITED STATES ALLOGENEIC CELL THERAPY Melbourne Australia
MESOBLAST AND LONZA ENTER INTO AGREEMENT FOR COMMERCIAL MANUFACTURE OF MESOBLAST'S POTENTIAL FIRST UNITED STATES ALLOGENEIC CELL THERAPY Melbourne Australia; October 17, 2019 and New York, USA; Basel, Switzerland; October 16, 2019 - Mesoblast (ASX:MSB; Nasdaq:MESO) and Lonza (SW
Read more →MESOAppendix 3B New Issue Announcement Quotation agreement 1 + Quotation of our additional + securities is in ASX's absolute discretion. ASX may quote the + securities on any conditions it decides. 2 We warrant the following
Company Notices Section Level 4, North Tower, Rialto Towers Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) This notice is given by Mesoblast Limited (ABN 68 109 431 870) (Mesoblast) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations A
Read more →MESOSeptember 2019 Chronic Low Back Pain Associated With Degenerative Disc Disease - A Major Unmet Medical Need Gr nenthal, a global leader in pain management, and Mesoblast have entered into a strategic partnership to devel
Chronic Low Back Pain Associated With Degenerative Disc Disease - A Major Unmet Medical Need Gr nenthal, a global leader in pain management, and Mesoblast have entered into a strategic partnership to develop and commercialize MPC-06-ID*, Mesoblast's Phase 3 allogeneic cell thera
Read more →MESOMESOBLAST COMPLETES SUCCESSFUL INSTITUTIONAL CAPITAL RAISING OF A$ 75 MILLION Melbourne, Australia
MESOBLAST COMPLETES SUCCESSFUL INSTITUTIONAL CAPITAL RAISING OF A$ 75 MILLION Melbourne, Australia; October 3, 2019; and New York, USA, October 2, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO), leader in cellular medicines for inflammatory diseases, announced today that it ha
Read more →MESOGr nenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain Aachen, Germany, and Melbourne, Australia,
Gr nenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain Aachen, Germany, and Melbourne, Australia, 10 September 2019 - Gr nenthal, a global leader in pain ma
Read more →MESOMesoblast Corporate Update: Analyst Call
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an analyst call today. The webcast will begin at 8.30pm EDT Monday September 9, 2019; 10.30
Read more →MESOMESOBLAST REPORTS 2019 FULL YEAR RESULTS Strong Operational Progress and Continued Growth in Revenues from Royalties Melbourne, Australia
MESOBLAST REPORTS 2019 FULL YEAR RESULTS Strong Operational Progress and Continued Growth in Revenues from Royalties Melbourne, Australia; August 30, 2019; and New York, USA, August 29, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported strong operational progress
Read more →MESOMesoblast Reports 2019 Full Year Results
NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported strong operational progress and financial highlights for the fourth quarter and full-year ended June 30, 2019 (FY2019). Mesoblast Chief Executive Dr Sil
Read more →MESOFDA PROVIDES GUIDANCE ON CLINICAL PATHWAY TO MARKETING APPLICATION FOR REVASCOR IN END-STAGE HEART FAILURE PATIENTS WITH AN LVAD Primary Endpoint of Confirmatory Trial to be Reduction in Major Mucosal Bleeding Events Mel
FDA PROVIDES GUIDANCE ON CLINICAL PATHWAY TO MARKETING APPLICATION FOR REVASCOR IN END-STAGE HEART FAILURE PATIENTS WITH AN LVAD Primary Endpoint of Confirmatory Trial to be Reduction in Major Mucosal Bleeding Events Melbourne, Australia; August 27, 2019, and New York, USA, Aug
Read more →MESOMesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019
NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss the financial results for the period ending June 30, 2019. The webcast wil
Read more →MESOREMESTEMCEL-L TO BE EVALUATED AS TREATMENT FOR CHRONIC GRAFT VERSUS HOST DISEASE IN PLANNED INVESTIGATOR-INITIATED TRIAL Melbourne, Australia
REMESTEMCEL-L TO BE EVALUATED AS TREATMENT FOR CHRONIC GRAFT VERSUS HOST DISEASE IN PLANNED INVESTIGATOR-INITIATED TRIAL Melbourne, Australia, August 14, 2019 and New York, USA, August 13, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for in
Read more →MESOMESOBLAST APPOINTS LEADING PHARMACEUTICAL INDUSTRY EXECUTIVE AS CHIEF MEDICAL OFFICER Melbourne, Australia
MESOBLAST APPOINTS LEADING PHARMACEUTICAL INDUSTRY EXECUTIVE AS CHIEF MEDICAL OFFICER Melbourne, Australia; August 12, 2019 and New York; USA; August 11, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, is pleased t
Read more →MESOMesoblast Quarterly Cash Flow Report
MELBOURNE, Australia and NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its operational highlights and its quarterly cash flows for the fourth quarter (fourth quarter FY2019) and 12 months ended June 30, 2019 (FY2019). Mesobla
Read more →MESOMESOBLAST QUARTERLY CASH FLOW REPORT RECORD REVENUES FROM JAPAN PRODUCT SALES FOR THE PERIOD ENDED JUNE 30, 2019 Melbourne, Australia
MESOBLAST QUARTERLY CASH FLOW REPORT RECORD REVENUES FROM JAPAN PRODUCT SALES FOR THE PERIOD ENDED JUNE 30, 2019 Melbourne, Australia, July 31, 2019 and New York, USA, July 30, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported its operational highlights and its quar
Read more →MESOCIRCULATION RESEARCH SPECIAL ARTICLE HIGHLIGHTS POTENTIAL OF MESOBLAST CELL THERAPY IN TREATMENT OF ADVANCED HEART FAILURE New York, USA; and Melbourne, Australia
CIRCULATION RESEARCH SPECIAL ARTICLE HIGHLIGHTS POTENTIAL OF MESOBLAST CELL THERAPY IN TREATMENT OF ADVANCED HEART FAILURE New York, USA; and Melbourne, Australia; July 25, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that premier cardiovascular journal Circ
Read more →MESONew Issue Announcement Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A "A" x 0.10 Note: number must be same as shown in Step 2 Not applicable Subtract "E" Note: number must
New Issue Announcement Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's propert
Read more →MESOMesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices
NEW YORK and MELBOURNE, Australia, June 24, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today that the United States Food and Drug Administration (FDA) has granted the company’s produ
Read more →MESOMESOBLAST TO HOST VIRTUAL SYMPOSIUM WITH KEY OPINION LEADER HIGHLIGHTING ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia
MESOBLAST TO HOST VIRTUAL SYMPOSIUM WITH KEY OPINION LEADER HIGHLIGHTING ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia; June 17, 2019: Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today annou
Read more →MESOMesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease
NEW YORK and MELBOURNE, Australia, June 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that it will host a virtual symposium to discuss Mesoblast’s product candidate, remestem
Read more →MESOMESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN New York, USA; and Melbourne, Australia
MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN New York, USA; and Melbourne, Australia; June 11, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expande
Read more →MESOMESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE PERIOD ENDED MARCH 31, 2019 Major corporate milestone achieved in initiating BLA filing with FDA for Mesoblast's cell therapy in the treatment of acu
MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE PERIOD ENDED MARCH 31, 2019 Major corporate milestone achieved in initiating BLA filing with FDA for Mesoblast's cell therapy in the treatment of acute graft versus host disease Melbourne, Australia, May 31
Read more →MESOMesoblast Financial Results Webcast for Period Ended March 31, 2019
MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the period ended March 31, 2019 in a webcast beginning at 6:30pm on Thursday, May 30, 2019 EDT; 8:30am Friday, May 31, 2019 AEST. The li
Read more →MESOMESOBLAST INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; and New York, USA
MESOBLAST INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR REMESTEMCEL-L IN THE TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; and New York, USA; May 30, 2019: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cell
Read more →MESOMESOBLAST KEYNOTE PRESENTATIONS TO FEATURE AT 2019 ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR CELL AND GENE THERAPY Melbourne, Australia; and New York, USA
MESOBLAST KEYNOTE PRESENTATIONS TO FEATURE AT 2019 ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR CELL AND GENE THERAPY Melbourne, Australia; and New York, USA; May 23, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases
Read more →MESOMESOBLAST TO PRESENT AT 2019 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE New York, USA; and Melbourne, Australia; May 17 , 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO), global leader in cellular medicines for in
MESOBLAST TO PRESENT AT 2019 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE New York, USA; and Melbourne, Australia; May 17, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate p
Read more →MESOMesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference
NEW YORK and MELBOURNE, Australia, May 17, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate presentation to the 2019 RBC Capital Markets Healthcare Conference
Read more →MESORule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16 Name of entity Mesoblast Limited ABN Quarter ended ("current quarter") 6
Quarterly report for entities subject to Listing Rule 4.7B Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16 Consolidated statement of cash flows Current quarter Year to date (9 months) US$ '000 US$ '000 1 Cash flows from operating activities
Read more →MESOFDA AGREES TO ROLLING REVIEW OF MESOBLAST'S BIOLOGIC LICENSE APPLICATION FOR ITS CELL THERAPY IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia
FDA AGREES TO ROLLING REVIEW OF MESOBLAST'S BIOLOGIC LICENSE APPLICATION FOR ITS CELL THERAPY IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia, April 16, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in c
Read more →MESOMESOBLAST TO PRESENT AT UPCOMING GLOBAL LIFE SCIENCE CONFERENCE IN LONDON New York, USA; and Melbourne, Australia
MESOBLAST TO PRESENT AT UPCOMING GLOBAL LIFE SCIENCE CONFERENCE IN LONDON New York, USA; and Melbourne, Australia; April 5, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, today announced an upcoming corporate presen
Read more →MESOMEMORANDUM OF UNDERSTANDING FOR CONFIRMATORY TRIAL TO SUPPORT MARKETING APPROVAL OF REVASCOR FOR REDUCTION OF GASTROINTESTINAL BLEEDING IN LVAD PATIENTS New York, USA; March 26 and Melbourne, Australia
MEMORANDUM OF UNDERSTANDING FOR CONFIRMATORY TRIAL TO SUPPORT MARKETING APPROVAL OF REVASCOR FOR REDUCTION OF GASTROINTESTINAL BLEEDING IN LVAD PATIENTS New York, USA; March 26 and Melbourne, Australia; March 27, 2019: Mesoblast Limited (ASX:MSB, Nasdaq:MESO), global leader in c
Read more →MESOMesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa
NEW YORK and MELBOURNE, Australia, March 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has filed to extend marketing approval of TEMCELL®1 HS Inj. for use in patients with Epidermolysis B
Read more →MESOU.S. HEALTHCARE LEADER JOSEPH R. SWEDISH APPOINTED MESOBLAST CHAIRMAN New York, USA, and Melbourne, Australia
U.S. HEALTHCARE LEADER JOSEPH R. SWEDISH APPOINTED MESOBLAST CHAIRMAN New York, USA, and Melbourne, Australia, March 22, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr Swedish will succeed outgoi
Read more →MESOMESOBLAST FEATURES AT UPCOMING U.S. INVESTOR CONFERENCES New York, USA; and Melbourne, Australia
MESOBLAST FEATURES AT UPCOMING U.S. INVESTOR CONFERENCES New York, USA; and Melbourne, Australia; March 13, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2018 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report i
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2018 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended 30 June 2018. Hal
Read more →MESOMESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE FIRST HALF ENDED DECEMBER 31, 2018 Strong cash reserves as Company prepares for potential US launch of remestemcel-L Melbourne, Australia
MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE FIRST HALF ENDED DECEMBER 31, 2018 Strong cash reserves as Company prepares for potential US launch of remestemcel-L Melbourne, Australia, February 21, 2019 and New York, USA, February 20, 2019: Mesoblast L
Read more →MESOFINAL PATIENT DOSED IN MESOBLAST PHASE 3 TRIAL OF REVASCOR CELL THERAPY FOR ADVANCED HEART FAILURE New York, USA; and Melbourne, Australia
FINAL PATIENT DOSED IN MESOBLAST PHASE 3 TRIAL OF REVASCOR CELL THERAPY FOR ADVANCED HEART FAILURE New York, USA; and Melbourne, Australia; February 19, 2019: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), a world leader in development and commercialization of cellular medicines, ann
Read more →MESOMesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018
NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December 31, 2018 in a webcast beginning at 4:30pm on Wednesday, February 20, 2019 EST; 8:30am Th
Read more →MESOHERCULES CAPITAL PROVIDES US$15M FROM EXISTING FACILITY FOR MESOBLAST TO ACCELERATE PRODUCT COMMERCIALIZATION PROGRAMS New York, USA and Melbourne, Australia
HERCULES CAPITAL PROVIDES US$15M FROM EXISTING FACILITY FOR MESOBLAST TO ACCELERATE PRODUCT COMMERCIALIZATION PROGRAMS New York, USA and Melbourne, Australia, January 14, 2019: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has drawn down a further US$15 mill
Read more →MESOMesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco
NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial and development plans for its lead cellular therapies to Biotec
Read more →MESOMesoblast Corporate Review
NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry. Two commercial products have already been approved and marketed by the
Read more →MESOMESOBLAST TO PRESENT AT 2019 BIOTECH SHOWCASE IN SAN FRANCISCO New York, USA; and Melbourne, Australia
MESOBLAST TO PRESENT AT 2019 BIOTECH SHOWCASE IN SAN FRANCISCO New York, USA; and Melbourne, Australia; December 24, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) will report on its Phase 3 trials and commercial plans at the upcoming Biotech Showcase 2019 to be held in San Fran
Read more →MESOMesoblast Makes Executive Appointment to Drive Product Commercialization
NEW YORK and MELBOURNE, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that it has appointed Eric Strati, PhD, to the new position of Senior Vice President, Commercial. He will drive commercial launch activities of the Compan
Read more →MESOMEETINGS HELD WITH FDA SUPPORT MESOBLAST'S PLANNED REGULATORY FILING FOR COMMERCIALIZATION OF REMESTEMCEL-L IN ACUTE GVHD New York, USA; and Melbourne, Australia
MEETINGS HELD WITH FDA SUPPORT MESOBLAST'S PLANNED REGULATORY FILING FOR COMMERCIALIZATION OF REMESTEMCEL-L IN ACUTE GVHD New York, USA; and Melbourne, Australia; December 13, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that recent meetings held with the Unite
Read more →MESOChairman's Address to the Mesoblast 2018 Annual General Meeting Welcome to the Mesoblast 2018 Annual General Meeting. There has been substantial progress made this year, with a number of key clinical and commercial highl
Chairman's Address to the Mesoblast 2018 Annual General Meeting Welcome to the Mesoblast 2018 Annual General Meeting. There has been substantial progress made this year, with a number of key clinical and commercial highlights. Specifically, our graft versus host disease produc
Read more →MESOTASLY AND MESOBLAST INITIATE DEVELOPMENT AND REGULATORY ACTIVITIES FOR MPC-150-IM HEART FAILURE CELL THERAPY IN CHINA New York, USA; and Melbourne, Australia
TASLY AND MESOBLAST INITIATE DEVELOPMENT AND REGULATORY ACTIVITIES FOR MPC-150-IM HEART FAILURE CELL THERAPY IN CHINA New York, USA; and Melbourne, Australia; November 26, 2018: Tasly Pharmaceutical Group and Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the firs
Read more →MESOMESOBLAST REPORTS FIRST QUARTER ENDED SEPTEMBER 30, 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Melbourne, Australia
MESOBLAST REPORTS FIRST QUARTER ENDED SEPTEMBER 30, 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Melbourne, Australia, November 16, 2018 and New York, USA, November 15, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided opera
Read more →MESOMesoblast Financial Results Webcast for Quarter Ended September 30, 2018
NEW YORK and MELBOURNE, Australia, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended September 30, 2018 in a webcast beginning at 4:30 pm on Thursday, November 15, 2018 EST; 8:30 am Friday, November 16,
Read more →MESOCLINICALLY MEANINGFUL OUTCOME IN NIH TRIAL OF MPC-150-IM FOR HEART FAILURE LVAD RECIPIENTS PROVIDES PATHWAY FOR POTENTIAL REGULATORY APPROVAL New York, USA
CLINICALLY MEANINGFUL OUTCOME IN NIH TRIAL OF MPC-150-IM FOR HEART FAILURE LVAD RECIPIENTS PROVIDES PATHWAY FOR POTENTIAL REGULATORY APPROVAL New York, USA; November 11, 2018 and Melbourne, Australia; November 12, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced th
Read more →MESOMesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions
NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in the treatment of en
Read more →MESOMESOBLAST EXPANDS PARTNERSHIP WITH JCR PHARMACEUTICALS FOR TREATMENT OF WOUND HEALING IN EPIDERMOLYSIS BULLOSA New York, USA; and Melbourne, Australia
MESOBLAST EXPANDS PARTNERSHIP WITH JCR PHARMACEUTICALS FOR TREATMENT OF WOUND HEALING IN EPIDERMOLYSIS BULLOSA New York, USA; and Melbourne, Australia; October 24, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuti
Read more →MESOMESOBLAST AND TASLY PHARMACEUTICAL GROUP COMPLETE TRANSACTION FOR STRATEGIC CARDIOVASCULAR PARTNERSHIP IN CHINA New York, USA, and Melbourne, Australia
MESOBLAST AND TASLY PHARMACEUTICAL GROUP COMPLETE TRANSACTION FOR STRATEGIC CARDIOVASCULAR PARTNERSHIP IN CHINA New York, USA, and Melbourne, Australia; October 12, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced completion of the transaction with Tasly Pharmace
Read more →MESOTRIAL RESULTS OF MESOBLAST CELL THERAPY IN END-STAGE HEART FAILURE SELECTED AS LATE-BREAKING PRESENTATION AT 2018 AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS New York, USA, and Melbourne, Australia
TRIAL RESULTS OF MESOBLAST CELL THERAPY IN END-STAGE HEART FAILURE SELECTED AS LATE-BREAKING PRESENTATION AT 2018 AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS New York, USA, and Melbourne, Australia; October 2, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced tha
Read more →MESOMESOBLAST HEART FAILURE CELL THERAPY FOR CHILDREN FEATURED AT REGENERATIVE SYMPOSIUM FOR CONGENITAL HEART DISEASE New York, USA, and Melbourne, Australia
MESOBLAST HEART FAILURE CELL THERAPY FOR CHILDREN FEATURED AT REGENERATIVE SYMPOSIUM FOR CONGENITAL HEART DISEASE New York, USA, and Melbourne, Australia; September 25, 2018: Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast's proprietary allogeneic mesench
Read more →MESOTASLY PHARMACEUTICAL GROUP RECEIVES ALL NECESSARY APPROVALS FOR TRANSACTION WITH MESOBLAST New York, USA, and Melbourne, Australia
TASLY PHARMACEUTICAL GROUP RECEIVES ALL NECESSARY APPROVALS FOR TRANSACTION WITH MESOBLAST New York, USA, and Melbourne, Australia; September 17, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all necess
Read more →MESOMESOBLAST REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Melbourne, Australia
MESOBLAST REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Melbourne, Australia; August 30, 2018; and New York, USA, August 29, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported strong financial results and provided operational
Read more →MESOMesoblast Provides Update on Transaction With Tasly Pharmaceutical Group
NEW YORK and MELBOURNE, Australia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has received People's Republic of China governmental approvals of Overseas Direct Investment from Tianjin Commission of
Read more →MESOMesoblast Financial Results Webcast for 2018 Financial Year
NEW YORK and MELBOURNE, Australia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) will report financial results for the financial year and fourth quarter ended June 30, 2018 in a webcast beginning at 6:00 pm on Wednesday, August 29, 2018 EDT; 8:00 am
Read more →MESOAppendix 3X Initial Director's Interest Notice Rule 3.19A.1 Appendix 3X Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents g
Initial Director's Interest Notice Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/9/2001 Name of entity
Read more →MESOMESOBLAST ENTERS INTO STRATEGIC CARDIOVASCULAR ALLIANCE FOR CHINA WITH TASLY PHARMACEUTICAL GROUP New York, USA, and Melbourne, Australia
MESOBLAST ENTERS INTO STRATEGIC CARDIOVASCULAR ALLIANCE FOR CHINA WITH TASLY PHARMACEUTICAL GROUP New York, USA, and Melbourne, Australia; July 17, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has entered into a strategic alliance with one of China's
Read more →MESORule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available.
Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public
Read more →MESOMesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease
NEW YORK and MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C. (NovaQuest) for the continued development and commercialization of its allogeneic pro
Read more →MESOMesoblast is committed to bringing to market disruptive cellular medicines to treat serious and life-threatening illnesses. Lengthy, Complex Process to Bring a New Medicine to Patients Ethically and with Integrity Discov
Road to Commercialization for Mesenchymal Lineage Cells Melbourne June 21, 2018 2018 ISSCR Annual Scientific Meeting Exhibit 99.1 Mesoblast is committed to bringing to market disruptive cellular medicines to treat serious and life-threatening illnesses. Lengthy, Complex Process
Read more →MESOKEY DAY 100 SURVIVAL OUTCOMES OF PHASE 3 TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE PRESENTED AT 2018 ISSCR ANNUAL MEETING New York, USA
KEY DAY 100 SURVIVAL OUTCOMES OF PHASE 3 TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE PRESENTED AT 2018 ISSCR ANNUAL MEETING New York, USA; June 20, 2018; and Melbourne, Australia; June 21, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced key Day 100 survival outcomes
Read more →MESOU.S. HEALTHCARE LEADER JOSEPH R. SWEDISH JOINS MESOBLAST BOARD New York, USA
U.S. HEALTHCARE LEADER JOSEPH R. SWEDISH JOINS MESOBLAST BOARD New York, USA, June 18, 2018 and Melbourne, Australia, June 19, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Joseph R. Swedish has joined its Board of Directors. Mr Swedish has more than two
Read more →MESOFINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE THIRD QUARTER ENDED MARCH 31, 2018 Melbourne, Australia
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE THIRD QUARTER ENDED MARCH 31, 2018 Melbourne, Australia; May 31, 2018; and New York, USA, May 30, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced strong financial results for the nine months ended March 31, 2
Read more →MESOMesoblast Appoints New Chief Financial Officer
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York. Chief Executive Dr Silviu Itescu welcomed the appointment of Mr Mu
Read more →MESOMesoblast Financial Results Webcast for Quarter Ended March 31, 2018
NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended March 31, 2018 in a webcast beginning at 6:30 pm on Wednesday, May 30, 2018 EST; 8:30 am Thursday, May 31, 2018 AEST.
Read more →MESOMESOBLAST PARTNERS WITH CARTHERICS TO DEVELOP 'OFF-THE-SHELF' CELL-BASED IMMUNOTHERAPIES FOR SOLID CANCERS Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR-T Cells New York, USA
MESOBLAST PARTNERS WITH CARTHERICS TO DEVELOP 'OFF-THE-SHELF' CELL-BASED IMMUNOTHERAPIES FOR SOLID CANCERS Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR-T Cells New York, USA; May 28, 2018 and Melbourne, Australia; May 29, 2018: Mesoblast Limited (ASX:
Read more →MESOMay 2018 The Manager Company Notices Section ASX Limited Level 4, North Tower, Rialto Towers 525 Collins Street MELBOURNE VIC 3000 Dear Sir/Madam Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) This no
15 May 2018 The Manager Company Notices Section ASX Limited Level 4, North Tower, Rialto Towers 525 Collins Street MELBOURNE VIC 3000 Dear Sir/Madam Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) This notice is given by Mesoblast Limited ACN 109 431 870 (Mes
Read more →MESOMESOBLAST PHASE 3 TRIAL RESULTS FOR ACUTE GRAFT VERSUS HOST DISEASE PRESENTED AT 2018 INTERNATIONAL SOCIETY FOR CELL AND GENE THERAPY ANNUAL MEETING New York, USA; and Melbourne, Australia
MESOBLAST PHASE 3 TRIAL RESULTS FOR ACUTE GRAFT VERSUS HOST DISEASE PRESENTED AT 2018 INTERNATIONAL SOCIETY FOR CELL AND GENE THERAPY ANNUAL MEETING New York, USA; and Melbourne, Australia; May 8, 2018: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced that results of th
Read more →MESOMesoblast Cell Therapies Featured at Vatican International Healthcare Conference
NEW YORK and MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Mesoblast’s proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican Conference on global healthcare initiatives held in Vatican City from April 26-28, 2018.
Read more →MESOMESOBLAST CLINICAL PROGRAM UPDATE FOR MPC-150-IM IN PATIENTS WITH CHRONIC HEART FAILURE New York, USA; and Melbourne, Australia
MESOBLAST CLINICAL PROGRAM UPDATE FOR MPC-150-IM IN PATIENTS WITH CHRONIC HEART FAILURE New York, USA; and Melbourne, Australia; April 18, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today provided an update on the Phase 3 and Phase 2b clinical trials of the Company's proprie
Read more →MESOMESOBLAST PHASE 3 CELL THERAPY TRIAL FOR CHRONIC LOW BACK PAIN COMPLETES ENROLLMENT New York, USA; and Melbourne, Australia
MESOBLAST PHASE 3 CELL THERAPY TRIAL FOR CHRONIC LOW BACK PAIN COMPLETES ENROLLMENT New York, USA; and Melbourne, Australia; March 29, 2018: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that enrollment has completed in the Phase 3 trial evaluating a single intra-disc
Read more →MESOMESOBLAST ENTERS INTO US$75 MILLION NON-DILUTIVE CREDIT FACILITY Funds to Advance Commercialization of Cell Therapy for Acute Graft Versus Host Disease and Other Late Stage Product Candidates Melbourne, Australia
MESOBLAST ENTERS INTO US$75 MILLION NON-DILUTIVE CREDIT FACILITY Funds to Advance Commercialization of Cell Therapy for Acute Graft Versus Host Disease and Other Late Stage Product Candidates Melbourne, Australia, March 7, 2018; and New York, USA, March 6, 2018: Mesoblast Limit
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2017 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report i
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2017 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended 30 June 2017. Hal
Read more →MESOMESOBLAST OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE HALF-YEAR ENDED DECEMBER 31, 2017 Melbourne, Australia
MESOBLAST OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE HALF-YEAR ENDED DECEMBER 31, 2017 Melbourne, Australia; February 28, 2018; and New York, USA, February 27, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today provided the market with an update on its operational
Read more →MESOPRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia
PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN MESOBLAST'S PHASE 3 CELL THERAPY TRIAL FOR ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia; February 22, 2018: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that the Phase 3 trial of its allogeneic me
Read more →MESOMesoblast to Present at 36th Annual J.P. Morgan Healthcare Conference
NEW YORK and MELBOURNE, Australia, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will present a corporate update at the 36th annual J.P. Morgan Healthcare Conference being held in San Francisco this week. The presentation will be made at 11:30am PDT
Read more →MESOMESOBLAST RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS CELL THERAPY IN HEART FAILURE PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES New York, USA; and Melbourne, Australia
MESOBLAST RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS CELL THERAPY IN HEART FAILURE PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES New York, USA; and Melbourne, Australia; December 21, 2017: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced tha
Read more →MESOMESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT New York, USA; and Melbourne, Australia
MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT New York, USA; and Melbourne, Australia; December 20, 2017: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced that the Phase 3 trial of its proprietary allogeneic mesenchymal
Read more →MESOMesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae New York, USA, Melbourne, Australia and Leuven, Belgium
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae New York, USA, Melbourne, Australia and Leuven, Belgium, December 14, 2017 - Mesoblast Limited (ASX: MSB; Nasdaq: MESO) and TiGenix NV (Eu
Read more →MESOMESOBLAST NAMED GLOBAL TECHNOLOGY LEADER IN CELL THERAPY INDUSTRY New York, USA
MESOBLAST NAMED GLOBAL TECHNOLOGY LEADER IN CELL THERAPY INDUSTRY New York, USA, December 7, 2017, and Melbourne, Australia; December 8, 2017: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Ind
Read more →MESOMESOBLAST OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2017 Melbourne, Australia
MESOBLAST OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2017 Melbourne, Australia; November 15, 2017; and New York, USA, November 14, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today provided the market with an update on its corpor
Read more →MESOMesoblast to Host First Quarter Financial Results Webcast and Conference Call
NEW YORK and MELBOURNE, Australia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced it will report financial results for the first quarter ended September 30, 2017 and provide a corporate update beginning at 4:30 pm ET on Tuesday, Novem
Read more →MESOMesoblast Phase 2 Trial Results Show Early and Durable Effects of Single Mesenchymal Precursor Cell Infusion in Biologic Refractory Rheumatoid Arthritis Patients
NEW YORK and MELBOURNE, Australia, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that results from the randomized, placebo-controlled Phase 2 trial of its proprietary allogeneic mesenchymal precursor cells (MPCs) over 52 weeks in pati
Read more →MESOMESOBLAST PRESENTS CORPORATE UPDATE AT 26 TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE New York, USA; and Melbourne, Australia
MESOBLAST PRESENTS CORPORATE UPDATE AT 26TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE New York, USA; and Melbourne, Australia; November 9, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today presented a corporate update at the 26th Annual Credit Suisse Healthcare Conference
Read more →MESOMesoblast Presents Corporate Update at 26TH Annual Credit Suisse Healthcare Conference
NEW YORK and MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today presented a corporate update at the 26th Annual Credit Suisse Healthcare Conference held in Scottsdale, Arizona. Chief Medical Officer Dr Donna Skerrett discussed
Read more →MESOAppendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Rules 4.7.3 and 4.10.3 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Introduced 01
Key to Disclosures Corporate Governance Council Principles and Recommendations Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations Introduced 01/07/14 Amended 02/11/15 Name of entity Mesoblast Limited ABN / ARBN Financial year ended: 109 4
Read more →MESOCLINICAL TRIAL OF MESOBLAST'S CELL THERAPY IN END-STAGE HEART FAILURE PATIENTS COMPLETES ENROLLMENT New York, USA; and Melbourne, Australia
CLINICAL TRIAL OF MESOBLAST'S CELL THERAPY IN END-STAGE HEART FAILURE PATIENTS COMPLETES ENROLLMENT New York, USA; and Melbourne, Australia; September 28, 2017: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that a multi-center team of researchers led by Icahn School o
Read more →MESOMESOBLAST PRESENTS CORPORATE UPDATES AT GLOBAL HEALTHCARE CONFERENCES New York, USA; and Melbourne, Australia
MESOBLAST PRESENTS CORPORATE UPDATES AT GLOBAL HEALTHCARE CONFERENCES New York, USA; and Melbourne, Australia; September 25, 2017: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced that the company will this week present corporate updates at the annual Cantor Fitzgerald
Read more →MESONot for release or distribution in the United States MESOBLAST SUCCESSFULLY COMPLETES A$50.7 MILLION ENTITLEMENT OFFER New York, USA; and Melbourne, Australia
Not for release or distribution in the United States MESOBLAST SUCCESSFULLY COMPLETES A$50.7 MILLION ENTITLEMENT OFFER New York, USA; and Melbourne, Australia; September 15, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it had successfully completed the fully
Read more →MESOMesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017
NEW YORK and MELBOURNE, Australia, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today reported its consolidated financial results and operational highlights for the three months ended June 30, 2017 (fourth quarter of 2017) and year ended June 30, 20
Read more →MESOMESOBLAST SUCCESSFULLY COMPLETES INSTITUTIONAL ENTITLEMENT OFFER FOR FULLY UNDERWRITTEN A$50.7MILLION CAPITAL RAISE New York, USA; and Melbourne, Australia
MESOBLAST SUCCESSFULLY COMPLETES INSTITUTIONAL ENTITLEMENT OFFER FOR FULLY UNDERWRITTEN A$50.7MILLION CAPITAL RAISE New York, USA; and Melbourne, Australia; August 29, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it had successfully completed the institutiona
Read more →MESOMESOBLAST OUTLINES POTENTIAL PATHWAY TO ACCELERATED MARKET ENTRY FOR MPC-150-IM IN ADVANCED CHRONIC HEART FAILURE • Advanced chronic heart failure (CHF) in patients with New York Heart Association (NYHA) Class III
MESOBLAST OUTLINES POTENTIAL PATHWAY TO ACCELERATED MARKET ENTRY FOR MPC-150-IM IN ADVANCED CHRONIC HEART FAILURE New York, USA; and Melbourne, Australia; August 23, 2017: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced plans to achieve an accelerated market entry of t
Read more →MESOPOSITIVE TRIAL RESULTS OF MESOBLAST CELL THERAPY IN POST-TRAUMATIC OSTEOARTHRITIS PUBLISHED IN ARTHRITIS RESEARCH & THERAPY • Over 250,000 Anterior Cruciate Ligament (ACL) tears occur annually in the United States
POSITIVE TRIAL RESULTS OF MESOBLAST CELL THERAPY IN POST-TRAUMATIC OSTEOARTHRITIS PUBLISHED IN ARTHRITIS RESEARCH & THERAPY New York; USA; and Melbourne, Australia; August 16, 2017: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the Phase 2a trial of its Mesenchym
Read more →MESOJuly 2017 The Manager Company Notices Section ASX Limited Level 4, North Tower, Rialto Towers 525 Collins Street MELBOURNE VIC 3000 Dear Sir/Madam Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) This n
10 July 2017 The Manager Company Notices Section ASX Limited Level 4, North Tower, Rialto Towers 525 Collins Street MELBOURNE VIC 3000 Dear Sir/Madam Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) This notice is given by Mesoblast Limited ACN 109 431 870 (Me
Read more →MESOMESOBLAST RHEUMATOID ARTHRITIS TRIAL RESULTS PRESENTED AT EULAR ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY New York, USA; and Melbourne, Australia
MESOBLAST RHEUMATOID ARTHRITIS TRIAL RESULTS PRESENTED AT EULAR ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY New York, USA; and Melbourne, Australia; June 22, 2017: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) announced that results from the randomized, placebo-controlled 48-patient Pha
Read more →MESOMESOBLAST OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 2017 Melbourne, Australia
MESOBLAST OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS FOR THE PERIOD ENDED MARCH 31, 2017 Melbourne, Australia; May 25, 2017; and New York, USA, May 24, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today provided the market with operational highlights and financial results
Read more →MESOMesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
NEW YORK and MELBOURNE, Australia, April 06, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$3.7 million from the Australian Government for Research & Development (R&D) activities conducted during the 2016 financial year.
Read more →MESOMESOBLAST RECEIVES A$3.7 MILLION FROM AUSTRALIAN GOVERNMENT FOR RESEARCH AND DEVELOPMENT ACTIVITIES New York, USA; and Melbourne, Australia
MESOBLAST RECEIVES A$3.7 MILLION FROM AUSTRALIAN GOVERNMENT FOR RESEARCH AND DEVELOPMENT ACTIVITIES New York, USA; and Melbourne, Australia; April 6, 2017: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that it has received A$3.7 million from the Australian Government
Read more →MESOFDA CLEARS HEART DISEASE TRIAL AT HARVARD'S BOSTON CHILDREN'S HOSPITAL USING MESOBLAST'S CELL THERAPY IN CHILDREN WITH CONGENITAL HEART DISEASE New York, USA, April 3; and Melbourne, Australia
FDA CLEARS HEART DISEASE TRIAL AT HARVARD'S BOSTON CHILDREN'S HOSPITAL USING MESOBLAST'S CELL THERAPY IN CHILDREN WITH CONGENITAL HEART DISEASE New York, USA, April 3; and Melbourne, Australia; April 4, 2017: Boston Children's Hospital, the pediatric teaching hospital of Harvard
Read more →MESOINDEPENDENT DATA MONITORING COMMITTEE INITIATES PROCESS FOR INTERIM ANALYSIS OF MES OBLAST'S PHASE 3 CHRONIC HEART FAILURE TRIAL New York, USA; and Melbourne, Australia
INDEPENDENT DATA MONITORING COMMITTEE INITIATES PROCESS FOR INTERIM ANALYSIS OF MESOBLAST'S PHASE 3 CHRONIC HEART FAILURE TRIAL New York, USA; and Melbourne, Australia; March 31, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that the Independent Data Monitori
Read more →MESOMESOBLAST RAISES US$40 MILLION New York, USA, and Melbourne, Australia
MESOBLAST RAISES US$40 MILLION New York, USA, and Melbourne, Australia; March 27, 2017: Mesoblast Limited (ASX: MSB, Nasdaq: MESO) today announced it has successfully completed a fully underwritten institutional placement of 26.25 million new shares (approx. 6% of issued capital
Read more →MESOMesoblast Raises US$40 Million
NEW YORK and MELBOURNE, Australia, March 27, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it has successfully completed a fully underwritten institutional placement of 26.25 million new shares (approx. 6% of issued capital) and has raised app
Read more →MESODURABLE THREE-YEAR OUTCOMES IN DEGENERATIVE DISC DISEASE AFTER A SINGLE INJECTION OF MESOBLAST'S CELL THERAPY Melbourne, Australia; and New York, USA
DURABLE THREE-YEAR OUTCOMES IN DEGENERATIVE DISC DISEASE AFTER A SINGLE INJECTION OF MESOBLAST'S CELL THERAPY Melbourne, Australia; and New York, USA; March 15, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced 36-month results from the randomized, placebo-control
Read more →MESOFDA GRANTS FAST TRACK DESIGNATION FOR MESOBLAST'S CELL THERAPY IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; and New York, USA
FDA GRANTS FAST TRACK DESIGNATION FOR MESOBLAST'S CELL THERAPY IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; and New York, USA, March 7, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that the United States Food and Drug Administration
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2016 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report i
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2016 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended 30 June 2016. Hal
Read more →MESOMesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 31, 2016
MELBOURNE, Australia and NEW YORK, Feb. 26, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with a strategic update, financial results for the half-year period ended December 31, 2016 (half-year FY2017), and operational highlights. Ou
Read more →MESOMesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast
NEW YORK and MELBOURNE, Australia, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended December 31, 2016 and provide a corporate update beginning at 5:00 pm Eastern Sta
Read more →MESOPUBLISHED STUDY RESULTS SHOW THAT MESOBLAST CELLS ADMINISTERED INTRAVENOUSLY SIGNIFICANTLY AMELIORATE JOINT DISEASE IN MODEL OF EARLY RHEUMATOID ARTHRITIS Study provides translational and mechanistic support for Phase 2
PUBLISHED STUDY RESULTS SHOW THAT MESOBLAST CELLS ADMINISTERED INTRAVENOUSLY SIGNIFICANTLY AMELIORATE JOINT DISEASE IN MODEL OF EARLY RHEUMATOID ARTHRITIS Study provides translational and mechanistic support for Phase 2 trial results of Mesoblast's cell therapy in patients with
Read more →MESOMesoblast Director Recognized by Peers for Cardiovascular Leadership
NEW YORK and MELBOURNE, Australia, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that its non-executive Director, Dr Eric A. Rose, was awarded the 2017 Earl Bakken Scientific Achievement Award by The Society of Thoracic Surgeons durin
Read more →MESOMesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia and NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO) (ASX:MSB) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference. Mesoblast’s management will present on Thursday, January 12, 2017 at 7:30 a.m. PST/2.30 a.m.
Read more →MESOMESOBLAST TO PRESENT AT 35 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Melbourne, Australia; and New York, USA
MESOBLAST TO PRESENT AT 35TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Melbourne, Australia; and New York, USA; January 11, 2017: Mesoblast (ASX: MSB; Nasdaq: MESO) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference. Mesoblast's management will pr
Read more →MESOMESOBLAST RECEIVES A$29.6 MILLION FOLLOWING SHARE ISSUE TO MALLINCKRODT New York, USA; and Melbourne, Australia
MESOBLAST RECEIVES A$29.6 MILLION FOLLOWING SHARE ISSUE TO MALLINCKRODT New York, USA; and Melbourne, Australia; January 9, 2017: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has received A$29.6 million (US$21.7 million) following issuance of 20.04 million
Read more →MESOMESOBLAST AND MALLINCKRODT ENTER INTO EQUITY PURCHASE AGREEMENT TO EXCLUSIVELY NEGOTIATE DEVELOPMENT AND COMMERCIALIZATION OF MESOBLAST'S CELL THERAPY PRODUCTS FOR CHRONIC LOW BACK PAIN AND ACUTE GRAFT VERSUS HOST DISEAS
MESOBLAST AND MALLINCKRODT ENTER INTO EQUITY PURCHASE AGREEMENT TO EXCLUSIVELY NEGOTIATE DEVELOPMENT AND COMMERCIALIZATION OF MESOBLAST'S CELL THERAPY PRODUCTS FOR CHRONIC LOW BACK PAIN AND ACUTE GRAFT VERSUS HOST DISEASE New York, USA; and Melbourne, Australia; December 23, 20
Read more →MESOUNITED STATES CONGRESS LEGISLATES NEW ACCELERATED APPROVAL PATHWAY FOR REGENERATIVE ADVANCED THERAPIES New York, USA; and Melbourne, Australia
UNITED STATES CONGRESS LEGISLATES NEW ACCELERATED APPROVAL PATHWAY FOR REGENERATIVE ADVANCED THERAPIES New York, USA; and Melbourne, Australia; December 9, 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today welcomed the passage of a Bill approving the 21st Century Cures Act
Read more →MESOMD ANDERSON CANCER CENTER AND NATIONAL INSTITUTES OF HEALTH TO FUND CLINICAL TRIAL COMBINING TWO PROPRIETARY MESOBLAST TECHNOLOGIES FOR RAPID ENGRAFTMENT OF STEM CELL TRANSPLANTS IN CANCER PATIENTS New York, USA; and Mel
MD ANDERSON CANCER CENTER AND NATIONAL INSTITUTES OF HEALTH TO FUND CLINICAL TRIAL COMBINING TWO PROPRIETARY MESOBLAST TECHNOLOGIES FOR RAPID ENGRAFTMENT OF STEM CELL TRANSPLANTS IN CANCER PATIENTS New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX
Read more →MESOMESOBLAST PROVIDES CORPORATE UPDATE AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2016 Melbourne, Australia
MESOBLAST PROVIDES CORPORATE UPDATE AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED SEPTEMBER 30, 2016 Melbourne, Australia; November 15, 2016; and New York, USA, November 14, 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today provided a quarterly corporate update on its o
Read more →MESOMesoblast Announces Successful Interim Futility Analysis In Phase 3 Trial For Acute Graft Versus Host Disease New York, USA; and Melbourne, Australia
Mesoblast Announces Successful Interim Futility Analysis In Phase 3 Trial For Acute Graft Versus Host Disease New York, USA; and Melbourne, Australia; November 14, 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that the Phase 3 trial of its intravenous product
Read more →MESOMesoblast to Host First Quarter Financial Results Conference Call and Webcast
NEW YORK and MELBOURNE, Australia, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first quarter ended September 30, 2016 and provide a corporate update beginning at 5:00 pm Eastern Time on Monda
Read more →MESOCorporate Governance Statement Mesoblast Limited (the Company or Mesoblast ) and its Board of Directors (the Board ) are committed to implementing and achieving an effective corporate governance framework to ensure that
Corporate Governance Statement Mesoblast Limited (the Company or Mesoblast) and its Board of Directors (the Board) are committed to implementing and achieving an effective corporate governance framework to ensure that the Company is managed effectively and in an honest and ethic
Read more →MESOMESOBLAST NAMED 2016 CELL THERAPY COMPANY OF THE YEAR AT FROST & SULLIVAN ASIA PACIFIC BEST PRACTICES AWARDS New York, USA, and Melbourne, Australia
MESOBLAST NAMED 2016 CELL THERAPY COMPANY OF THE YEAR AT FROST & SULLIVAN ASIA PACIFIC BEST PRACTICES AWARDS New York, USA, and Melbourne, Australia; October 18, 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it received the Frost & Sullivan Asia Pacific 2
Read more →MESOMESOBLAST JAPAN STRATEGY HIGHLIGHTED AT AUSTRALIA-JAPAN BUSINESS COUNCIL ANNUAL MEETING New York, USA, and Melbourne, Australia
MESOBLAST JAPAN STRATEGY HIGHLIGHTED AT AUSTRALIA-JAPAN BUSINESS COUNCIL ANNUAL MEETING New York, USA, and Melbourne, Australia; October 12, 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) yesterday gave a strategic update on its product commercialization plans in Japan. Mesobl
Read more →MESOPHASE 2 TRIAL RESULTS OF MESOBLAST'S CELL THERAPY IN DIABETIC KIDNEY DISEASE PUBLISHED New York; USA; and Melbourne, Australia
PHASE 2 TRIAL RESULTS OF MESOBLAST'S CELL THERAPY IN DIABETIC KIDNEY DISEASE PUBLISHED New York; USA; and Melbourne, Australia; October 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that results from the randomized, placebo-controlled Phase 2 trial of its pro
Read more →MESOMESOBLAST APPOINTS BILL BURNS, FORMER CHIEF EXECUTIVE OF ROCHE PHARMACEUTICALS, AS VICE CHAIRMAN New York, USA, and Melbourne, Australia
MESOBLAST APPOINTS BILL BURNS, FORMER CHIEF EXECUTIVE OF ROCHE PHARMACEUTICALS, AS VICE CHAIRMAN New York, USA, and Melbourne, Australia; September 1, 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Mr William (Bill) A. Burns, former Chief Executive Officer
Read more →MESOMesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016
MELBOURNE, Australia and NEW YORK, Aug. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today reported its consolidated financial results and operational highlights for the three months ended 30 June 2016 (fourth quarter of 2016) and year ended 30 June 2016
Read more →MESOMesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast
NEW YORK and MELBOURNE, Australia, Aug. 19, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the fourth quarter and full year ended June 30, 2016 and provide a corporate update beginning at 7:00 pm Eastern Tim
Read more →MESOMESOBLAST STRENGTHENS KEY UNITED STATES PATENT PORTFOLIO FOR THE TREATMENT OF RHEUMATIC DISEASES New York, USA, and Melbourne, Australia
MESOBLAST STRENGTHENS KEY UNITED STATES PATENT PORTFOLIO FOR THE TREATMENT OF RHEUMATIC DISEASES New York, USA, and Melbourne, Australia; August 17, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that its intellectual property portfolio covering the use of its Me
Read more →MESOPHASE 2 TRIAL RESULTS OF MESOBLAST'S CELL THERAPY SHOW DOSE-RELATED IMPROVEMENTS IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS Key points: The biologic refractory rheumatoid arthritis (RA) population accounts for approxima
PHASE 2 TRIAL RESULTS OF MESOBLAST'S CELL THERAPY SHOW DOSE-RELATED IMPROVEMENTS IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS New York; USA; and Melbourne, Australia; 9 August 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), today announced that a single intravenous infusion of it
Read more →MESOAppendix 4C Quarterly report for entities admitted on the basis of commitments Rule 4.7B Appendix 4C Quarterly report for entities admitted on the basis of commitments Introduced 31/03/010 Amended 30/09/01, 24/10/05, 17/
Quarterly report for entities admitted on the basis of commitments for entities admitted on the basis of commitments Introduced 31/03/010 Amended 30/09/01, 24/10/05, 17/12/10 Consolidated statement of cash flows Current quarter Year to date (12 months) US$ '000
Read more →MESOMesoblast’s Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
MELBOURNE, Australia and NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the 24-month results from the 100-patient, four-arm, randomized, placebo-controlled Phase 2 trial of its chronic low back pain (CLBP) product candid
Read more →MESOMESOBLAST PROVIDES UPDATE ON HEART FAILURE TRIAL AND FUNDING OF CLINICAL OPERATIONS Highlights Interim Analysis to assess heart failure Phase 3 trial s primary endpoint to read-out meaningful data in Q1 2017 The anticipa
MESOBLAST PROVIDES UPDATE ON HEART FAILURE TRIAL AND FUNDING OF CLINICAL OPERATIONS New York, USA; and Melbourne, Australia; 1 July 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced plans for an early data readout on its Phase 3 chronic heart failure trial, mater
Read more →MESOMESOBLAST PROVIDES UPDATE ON GLOBAL HEART FAILURE PROGRAM Key points: Mesoblast regains worldwide rights to cardiovascular field for its cell therapy platform Lead product candidate in cardiovascular portfolio is MPC-150
MESOBLAST PROVIDES UPDATE ON GLOBAL HEART FAILURE PROGRAM New York, USA; and Melbourne, Australia; 14 June 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that it has regained full worldwide rights and full strategic flexibility to exploit its mesenchymal precurs
Read more →MESOMESOBLAST RECEIVES $6.2 MILLION FROM AUSTRALIAN GOVERNMENT FOR RESEARCH AND DEVELOPMENT ACTIVITIES New York, USA; and Melbourne, Australia; 20 May 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that it ha
MESOBLAST RECEIVES $6.2 MILLION FROM AUSTRALIAN GOVERNMENT FOR RESEARCH AND DEVELOPMENT ACTIVITIES New York, USA; and Melbourne, Australia; 20 May 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that it has received $6.2 million from the Australian Government fo
Read more →MESOMESOBLAST REPORTS FINANCIAL RESULTS FOR PERIOD ENDED 31 MARCH 2016 AND PROVIDES CORPORATE UPDATE Melbourne, Australia (10 May 2016); and New York, USA (9 May 2016): Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today repo
MESOBLAST REPORTS FINANCIAL RESULTS FOR PERIOD ENDED 31 MARCH 2016 AND PROVIDES CORPORATE UPDATE Melbourne, Australia (10 May 2016); and New York, USA (9 May 2016): Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today reported its consolidated financial results and operational high
Read more →MESOMesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update
MELBOURNE, Australia and NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016. In line with previous guidance, t
Read more →MESOMesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast
NEW YORK and MELBOURNE, Australia, May 06, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on
Read more →MESOAppendix 4C Quarterly report for entities admitted on the basis of commitments Rule 4.7B Appendix 4C Quarterly report for entities admitted on the basis of commitments Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/1
admitted on the basis of commitments for entities admitted the basis of commitments Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10 Name of entity Mesoblast Limited ABN Quarter ended ( current quarter ) 68 109 431 870 31 March 2016 Consolidated stateme
Read more →MESOMesoblast Limited ABN 68 109 431 870 19 April 2016 Corporate Headquarters Level 38 55 Collins Street Melbourne, Victoria 3000 AUSTRALIA T +61 3 9639 6036 F +61 3 9639 6030 Manager Market Announcements Office ASX Limited
Mesoblast Limited ABN 68 109 431 870 19 April 2016 Corporate Headquarters Level 38 55 Collins Street Melbourne, Victoria 3000 AUSTRALIA T +61 3 9639 6036 F +61 3 9639 6030 Manager Market Announcements Office ASX Limited Exchange Centre 20 Bridge Street Sydney NSW 2000 U
Read more →MESOMESOBLAST CELL THERAPY SHOWS DISEASE MODIFYING EFFECTS ON KNEE OSTEOARTHRITIS Clinical Results Presented at 2016 Osteoarthritis Research Society International Congress Melbourne, Australia; and New York, USA; 1 April 201
MESOBLAST CELL THERAPY SHOWS DISEASE MODIFYING EFFECTS ON Clinical Results Presented at 2016 Osteoarthritis Research Society International Congress Melbourne, Australia; and New York, USA; 1 April 2016: Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that results fr
Read more →MESOMesoblast Cell Therapy Shows Disease Modifying Effects on Knee Osteoarthritis
NEW YORK and MELBOURNE, Australia, April 01, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results from its Phase 2a trial in patients with post-traumatic knee injury to the anterior cruciate ligament (ACL) showed that a single intra-arti
Read more →MESOKEY UNITED STATES PATENT GRANTED FOR CELL-BASED TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER RHEUMATIC CONDITIONS New York, USA, and Melbourne, Australia; 24 March 2016 : Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today ann
KEY UNITED STATES PATENT GRANTED FOR CELL-BASED TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER RHEUMATIC CONDITIONS New York, USA, and Melbourne, Australia; 24 March 2016 : Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the United States Patent and Trademark Office
Read more →MESONEW MESOBLAST CELL TARGETING TECHNOLOGY SHOWS POTENTIAL TO INDUCE DURABLE REVERSAL OF TYPE 1 DIABETES Mesoblast Exclusively Licenses Technology To Enhance Natural Homing Properties Of Cells To Sites Of Inflammation New Y
NEW MESOBLAST CELL TARGETING TECHNOLOGY SHOWS POTENTIAL TO INDUCE DURABLE REVERSAL OF TYPE 1 DIABETES Mesoblast Exclusively Licenses Technology To Enhance Natural Homing Properties Of Cells To Sites Of Inflammation New York, USA; and Melbourne, Australia; 17 March 2016: Mesob
Read more →MESOMesoblast’s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease
NEW YORK and MELBOURNE, Australia, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced that results have been presented showing that use of its proprietary Tier 1 mesenchymal stem cell product candidate remestemcel-L (MSC-100-IV) demonstra
Read more →MESOMESOBLAST CELL THERAPY SHOWS CLINICAL BENEFIT IN FIRST COHORT OF PATIENTS WITH BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS New York; USA; and Melbourne, Australia; 16 February 2016 : Mesoblast Limited (ASX:MSB; Nasdaq:MESO)
MESOBLAST CELL THERAPY SHOWS CLINICAL BENEFIT IN FIRST COHORT OF PATIENTS WITH BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS New York; USA; and Melbourne, Australia; 16 February 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), today announced results from the first cohort of its ong
Read more →MESOMesoblast Reports on First Half and Second Quarter Financial Results
MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported financial results and operational highlights for the 1H/2Q ended 31 December 2015. Financial Highlights (USD) At 31 December 2015, the Company had cash
Read more →MESOMesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2015 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report i
and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2015 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended 30 June 2015. Ha
Read more →MESOPHASE 3 HEART FAILURE TRIAL SIZE TO BE SUBSTANTIALLY REDUCED FOLLOWING FDA DISCUSSIONS New York, USA; and Melbourne, Australia; 11 January 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the size of t
PHASE 3 HEART FAILURE TRIAL SIZE TO BE SUBSTANTIALLY REDUCED FOLLOWING FDA DISCUSSIONS New York, USA; and Melbourne, Australia; 11 January 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure (CHF) of
Read more →MESOMesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am
Read more →MESOMESOBLAST PROVIDES STRATEGIC UPDATE AND REPORTS ON FIRST QUARTER FINANCIAL RESULTS Materially Strengthened Cash Reserves First Royalties From TEMCELL Product Sales Expected In Q1 2016 Resources Prioritized On Tier 1 Prod
MESOBLAST PROVIDES STRATEGIC UPDATE AND REPORTS ON FIRST QUARTER FINANCIAL RESULTS Materially Strengthened Cash Reserves First Royalties From TEMCELL Product Sales Expected In Q1 2016 Resources Prioritized On Tier 1 Product Candidates Cash Managed To Extend Runway And Achieve
Read more →MESOMesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015
MELBOURNE, Australia and NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September 2015 after the close of the Nasdaq market on Wednesday 16 December. Mesoblast managem
Read more →MESOAppendix 3Y Change of Director s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Director s Interest Notice Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and Introduced 30/09/01 Amended 01/01/11 Name of entity Mesoblast
Read more →MESOMesoblast’s Japan Licensee Receives Pricing for TEMCELL HS Inj. for Treatment of Acute Graft Versus Host Disease
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received notification that the Japanese Government’s National Health Insurance (NHI) body h
Read more →MESOMesoblast Investor Update
MELBOURNE, Australia and NEW YORK, Nov. 23, 2015 (GLOBE NEWSWIRE) -- The Mesoblast Board and management are committed to delivering the Tier 1 product milestones as set out in the recent F-1 registration statement using the Company’s existing cash reserves, including the proceeds
Read more →MESOMesoblast Lists On Nasdaq
MELBOURNE, Australia and NEW YORK, Nov. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol 'MESO'. Mesoblast expects to receive gross proceeds of approximately A$95.8 mi
Read more →MESOMesoblast Announces Pricing Of Public Offering On Nasdaq
NEW YORK and MELBOURNE, Australia, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB), a world leader in the development of innovative cell-based medicines, today announced the pricing of its public offering of 7,479,617 American Depositary Shares (ADSs),
Read more →MESOMesoblast Chairman's Address to 2015 Annual General Meeting
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting. This has been another exciting and productive year in the history of our Company. We are very glad to report that following recent important developments, we expect to
Read more →MESOMesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031, developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co.
Read more →MESOMesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important changes to its Phase 3 chronic heart failure program. At 30 June 2015, the Com
Read more →MESOMesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation an
Read more →MESOMesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
NEW YORK and MELBOURNE, Australia, April 7, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the European Medicines Agency (EMA), it intends to expand the Phase 3 clinical program of
Read more →MESOMesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases, Stroke, and Other Vascular Conditions
NEW YORK and MELBOURNE, Australia, March 26, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Japanese Patent Office has allowed a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the
Read more →MESOMesoblast Selected for Fast Track Access to Potential Investment Incentives in Japan
NEW YORK and MELBOURNE, Australia, March 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track acc
Read more →MESOMesoblast Reports 2015 Half-Year Results
NEW YORK CITY, N.Y., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today provided its 2015 half-year financial results and operational highlights. Mesoblast held cash reserves of $149.2 million at 31 December 2014. During the reporting period, Meso
Read more →MESOMesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference
NEW YORK and MELBOURNE, Australia, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today presented positive 24-month results from its Phase 2 program for chronic low back pain at the JP Morgan 33rd Annual Healthcare Conference being held in San Franci
Read more →MESOMesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting
NEW YORK and MELBOURNE, Australia, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS) Annual Meeting, the premier global conference for spine disease professionals. The k
Read more →MESOMesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR Pharmaceuticals Co Ltd (JCR), has filed with the Japanese Pharmaceuticals and Medical Devic
Read more →MESOMesoblast Unveils Path to Bring Its Key Products to Market
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its strategy to prioritize and bring to market clinically differentiated products based
Read more →MESOMesoblast Accelerates Plans For Commercialization Manufacturing Operations In Singapore
NEW YORK and MELBOURNE, Australia, May 27, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it is bringing forward plans for its commercial manufacturing operations in line with anticipated product launches in th
Read more →MESOMesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the product Prochymal , which was acquired as part of the entire culture-expanded m
Read more →MESOMesoblast Reports Strong Half-Year Financial Results
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and operational highlights. Over the reporting period, progression of the Company's Mes
Read more →MESOMesoblast Reports Positive Type 2 Diabetes Trial Results
NEW YORK and MELBOURNE, Australia, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced top-line results from the Phase 2 trial of its proprietary Mesenchymal Precursor Cells (MPCs) in subjects with type 2 diabete
Read more →MESOMesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
NEW YORK and MELBOURNE, Australia, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left ventricular assist device (LVAD) heart pump to maintain circulation may obtain specific
Read more →MESOMesoblast's Mesenchymal Precursor Cells Induce Functional Recovery in Ischemic Stroke Model
NEW YORK and MELBOURNE, Australia, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced positive preclinical trial results which demonstrated that its proprietary Mesenchymal Precursor Cells (MPCs) could improve
Read more →MESOMESOBLAST UPDATES MARKET ON REGISTRATION PLANS FOR GVHD CELL PRODUCT IN JAPAN
MELBOURNE, Australia and NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today updated the market on product registration plans in Japan for its proprietary culture-expanded Mesenchymal Stem Cells (MSCs) in the t
Read more →MESOMesoblast, Intrexon and ZIOPHARM to Target Cancers
MELBOURNE, Australia and NEW YORK, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a bio
Read more →MESOMESOBLAST ACQUIRES OSIRIS' CULTURE EXPANDED STEM CELL THERAPEUTIC BUSINESS
MELBOURNE, Australia and NEW YORK, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced the acquisition of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics (Nasdaq:OSIR) by
Read more →MESOMesoblast's Phase 2 Trial For Lumbar Spinal Fusion Selected For Presentation at Premier Spine Conference
MELBOURNE, Australia and NEW YORK, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the Phase 2 clinical trial using the Company's proprietary Mesenchymal Precursor Cells (MPCs) for lumbar spinal fusio
Read more →MESOMesoblast's Strong Cash Position Enables Execution of Late-Stage Clinical Trials
NEW YORK and MELBOURNE, Australia, Aug. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY), today provided its full year financial results. The Company stated that it had total funds of $315.3 million at 30 June 2013, compared
Read more →MESOMesoblast Receives $4.3 Million from Australian Government for Adult Stem Cell Pipeline Development
NEW YORK and MELBOURNE, Australia, July 18, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited today announced that it has received approximately $4.3 million under the Australian Government's Innovation Australia Research and Development (R &D) Tax Incentive Program for R &D activities
Read more →MESOMesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy
NEW YORK, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Mesoblast has received ethics approvals to begin a clinical trial of its proprietary allogeneic, or "off-the-shelf", adult Mesenchymal Precursor Cells (MPCs) in people with chronic kidney disease and type 2 diabetes Trial is a r
Read more →MESOMESOBLAST'S PRECLINICAL TRIAL RESULTS OF INTRACORONARY CELL THERAPY PUBLISHED IN CIRCULATION RESEARCH
NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) -- Mesoblast's preclinical trial results of its allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPC) delivered by intracoronary infusion in acute myocardial infarction (AMI) have been published in the May 2013 issue of Circulat
Read more →MESOMESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR
Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100 patients enrolled A pre-specified interim analysis of Phase 2 trial results was performed
Read more →MESOMESOBLAST CHIEF EXECUTIVE HONOURED AT THE VATICAN WITH INAUGURAL PONTIFICAL AWARD FOR INNOVATION
NEW YORK and MELBOURNE, Australia, April 12, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB, USOTC:MBLTY) is pleased to announce that its Chief Executive Professor Silviu Itescu today received the inaugural 'Key Innovation Award 2013' from the P
Read more →MESOMesoblast Completes A$170m Private Placement
MELBOURNE, Australia, March 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has completed a private placement of its shares, raising A$170 million. Mesoblast now has cash reserves of approximately A$332
Read more →MESOMesoblast Reports Half-Year 2013 Financial Results
NEW YORK, Feb. 10, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today provided its half-year 2013 financial results, as well as a strategic update on the key areas of product development for its Mesenchymal Precursor Cell (MPC) platform technology, particu
Read more →MESOMesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis
Mesoblast receives clearance from United States Food and Drug Administration (FDA) to begin Phase 2 trial of proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in patients with active Rheumatoid Arthritis (RA) Trial will be randomized, double-blind pl
Read more →MESOMesoblast's NeoFuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial
Phase 2 trial results using Mesoblast's allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) demonstrated rates of fusion success that were comparable to the gold standard bone autograft MPCs were well tolerated with no cell-related serious adverse events and no ev
Read more →Competitive Position
How MESO ranks across every disease it competes inCompetitive Position is a premium feature
See how MESO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial